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1. Resumo 
 
A malária é uma das doenças infecciosas mais importantes em todo o mundo, 
afectando cerca de 200-300 milhões de pessoas todos os anos. A infecção por malária 
é causada por um protozoário do filo Apicomplexa do género Plasmodium. Estes 
parasitas possuem um ciclo de vida complexo que requer um mosquito Anopheles como 
vector e um hospedeiro vertebrado. Em mamíferos, o ciclo de vida do parasita inclui 
uma fase hepática, assintomática, seguida de uma fase eritrocítica, onde surgem os 
sintomas de malária e a patologia. Na fase eritrocítica, o parasita no estádio de 
merozoíto, oriundo da fase hepática, entra na circulação sanguínea e invade um glóbulo 
vermelho (GV) onde se replica assexuadamente. O desenvolvimento intra-eritrocítico do 
parasita é constituído por vários estádios que incluem um forma inicial em anel, seguida 
de uma fase de trofozoíto maduro que por sua vez se desenvolve em esquizonte. 
Durante a maturação do esquizonte ocorre um processo de reprodução assexuada 
designado esquizogenia através do qual são originados vários merozoítos, que levam à 
ruptura do glóbulo vermelho. Após a ruptura, os merozoítos libertados re-iniciam o ciclo 
intra-eritrocítico, invadindo novos glóbulos vermelhos. Este ciclo de ruptura e re-invasão 
é responsável pela hemólise e consequente anemia que se verifica durante uma 
infecção por malária. 
 
Apesar da infecção por malária geralmente não originar um perfil clínico grave, alguns 
casos resultam em patologia severa, responsável pela morte de aproximadamente 1 
milhão de pessoas anualmente. Em humanos, a malária severa ocorre sobretudo 
devido a infecções por Plasmodium falciparum. A malária cerebral (MC) é uma das 
formas mais letais de malária severa ainda sem tratamento e afectando sobretudo 
crianças com idades inferiores a 5 anos. A patogénese da MC é muito complexa, e os 
mecanismos que levam ao desenvolvimento da doença ainda são pouco conhecidos. 
No entanto, a patogénese da MC tem sido explicada por três processos principais: 
sequestração, inflamação e disfunção hemostática. 
 
Uma melhor compreensão da patogénese da MC é fundamental para o 
desenvolvimento de novas estratégias terapêuticas contra este síndroma. O modelo de 
malária cerebral experimental (MCE) em murganhos C57BL/6 infectados com P. 
berghei ANKA (PbA), tem contribuído de forma decisiva para este conhecimento. Este 
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modelo apresenta várias caraterísticas histopatológicas e imunológicas semelhantes à 
neuropatologia humana. No entanto, uma das principais diferenças é o tipo de células 
envolvido no processo de sequestração. Nos humanos, sabe-se que a sequestração de 
glóbulos vermelhos infectados (GVis) na microvasculatura do cérebro é um processo 
crucial para o desenvolvimento da patologia. Contudo, em murganhos, os leucócitos 
são as células que maioritariamente sequestram no cérebro. Esta observação tem 
lançado dúvidas sobre a importância da sequestração de GVis no cérebro no modelo de 
murganho, e contribuído para a controvérsia existente relativamente ao uso deste 
modelo como um modelo adequado ao estudo da MC. Desta forma, é importante 
compreender o papel da sequestração de glóbulos vermelhos infectados no cérebro e o 
seu papel no desenvolvimento da MCE em murganhos C57BL/6 infectados com PbA. 
 
Para além do processo de sequestração, também a inflamação e a disfunção do 
sistema hemostático têm sido envolvidos na patogénese da MC. Pensa-se que uma 
resposta imune exacerbada contra o parasita poderá desencadear eventos patogénicos 
que se sobrepõem à função protectora do sistema imunitário, entre os quais a 
neuroinflamação será um processo crítico. Neste contexto, várias citocinas pró-
inflamatórias têm sido implicadas na MC, como o factor de necrose tumoral-α (TNF-α), o 
interferão-γ (IFN-γ) e a linfotoxina-α (LT-α). A expressão no endotélio vascular cerebral 
de moléculas de adesão celular, como a molécula de adesão intercelular-1 (ICAM-1), 
parece também ser um processo importante para a patologia, mediando a sequestração 
de leucócitos e GVis no cérebro. Para além disto, o recrutamento de linfócitos T, em 
particular de linfócitos T CD8+, para a microvasculatura cerebral desempenha um papel 
crucial na patogénese da MCE. Nesse sentido, a expressão no cérebro de quimiocinas, 
i.e. moléculas quimiotácticas que dirigem a migração de leucócitos, tais como a proteína 
induzida pelo IFN-γ-10 (IP-10), foi demonstrada contribuir para o estabelecimento da 
patologia em murganhos. Por outro lado, pensa-se que o desequilíbrio hemostático 
também desempenhe um papel importante na patogénese da MC. A existência de um 
estado pro-coagulante e o potencial papel das plaquetas na sequestração de GVis e na 
congestão vascular parecem ser intervenientes importantes neste processo.  
A orquestração dos processos de sequestração, inflamação e desequilíbrio hemostático 
parecem culminar na lesão da barreira hemato-encefálica, um processo que parece 
decisivo na manifestação clínica da MC e cuja extensão poderá ditar sequelas 
neurológicas permanentes ou mesmo a morte. 
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O conhecimento mais aprofundado dos factores e mecanismos implicados na MC tem 
mostrado que várias moléculas do hospedeiro participam no desenvolvimento da 
doença, quer com uma acção patogénica, quer com uma função essencialmente 
protectora. Foi demonstrado recentemente que a expressão da heme oxigenase-1 (HO-
1) do hospedeiro tem um papel preponderante em determinar a susceptibilidade à MC. 
De facto, foi provada uma importante acção protectora da enzima contra o 
desenvolvimento da MCE, que parece ser mediada sobretudo pela produção de 
monóxido de carbono (CO), um produto final da actividade da HO-1. 
Surpreendentemente, verificou-se que a administração de CO por inalação a 
murganhos C57BL/6 infectados com PbA, impedia o desenvolvimento de MCE em 
100% dos casos. O efeito protector do CO manifestava-se na inibição da congestão 
microvascular cerebral, da neuroinflamação e do aumento da permeabilidade da 
barreira hemato-encefálica. A inibição da neuroinflamação reflectia-se na redução da 
expressão no cérebro de TNF-α, IFN-α, LT-α e ICAM-1 e inibição do recrutamento de 
células T CD8+ para o cérebro. O efeito terapêutico exercido pelo CO foi sugerido 
depender da supressão da oxidação da hemoglobina (Hb) em circulação, através da 
ligação do CO à Hb, formando carboxihemoglobina. Isto impediria a conversão da Hb 
em metahemoglobina e a libertação de heme, uma molécula com efeitos inflamatórios e 
oxidantes nocivos.  
 
Neste trabalho pretendeu-se aprofundar o mecanismo protector do CO contra a MCE, 
em particular no que respeita ao seu efeito na sequestração de glóbulos vermelhos 
infectados no cérebro. Utilizou-se um método desenvolvido recentemente que permite 
revelar em tempo real a presença do parasita, por detecção de bioluminescência. Os 
murganhos foram infectados com um parasita PbA transgénico que expressa luciferase, 
o que permitiu a sua detecção nos órgãos por emissão de bioluminescência. Verificou-
se que apesar do cérebro ser o órgão com menor acumulação de GVis em murganhos 
C57BL/6 infectados com PbA, a presença de parasita neste órgão é nitidamente 
detectável por este sistema. De especial importância é o facto de se verificar que a 
acção protectora do CO parece estar associada com uma diminuição evidente da 
sequestração de GVis no cérebro. Estes resultados, para além de indicarem que o 
mecanismo protector do CO inclui a redução da sequestração de parasita no cérebro, 
reforçam que o processo de sequestração cerebral de GVis é fundamental para o 
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desenvolvimento da MCE, reforçando a relevância do modelo de murganho C57BL/6 
infectado com PbA como um modelo muito semelhante à patologia humana e, por isso, 
adequado ao seu estudo. Adicionalmente, confirmou-se que o CO tem uma actividade 
anti-inflamatória e uma acção anti-quimiotáctica, uma vez que inibe a expressão de IP-
10 no cérebro. Isto parece contribuir para uma menor migração de células T CD8+ para 
o cérebro, processo crucial para a patologia no murganho.  
 
O segundo objectivo deste trabalho foi estudar a bio-actividade e o potencial terapêutico 
das moléculas libertadoras de CO (CO-RMs) no modelo experimental de malária 
cerebral. De facto, tem sido demonstrado que estas moléculas reproduzem os efeitos 
anti-oxidantes e anti-inflamatórios do CO em vários modelos de patologia, afigurando-se 
como potenciais novos fármacos. Uma das vantagens destas moléculas é a 
possibilidade de exercerem os efeitos benéficos do CO sem o perigo de toxicidade 
associado ao CO por inalação.     
 
Surpreendentemente, observámos que a administração de CORM-2 com uma 
concentração de 20 mg/kg de peso corporal, por via intravenosa, duas vezes por dia, do 
dia 2 ao 3 após infecção, confere uma protecção de 100% contra o desenvolvimento de 
MCE. Adicionalmente, verificou-se que o CORM-2 não produz carboxihemoglobina, 
indicando que não induz a mesma toxicidade que o CO inalado, o que tem especial 
relevância para futuras aplicações terapêuticas. Tal como para o CO administrado por 
inalação, verificou-se uma diminuição nos níveis de metahemoglobina em circulação em 
murganhos tratados com CORM-2, reforçando o papel benéfico do CO no controlo do 
stress oxidativo causado pela infecção. Os resultados mostram também que o CORM-2 
diminui a sequestração de Gvis no cérebro e a neuroinflamação em murganhos 
infectados com PbA, tal como anteriormente demonstrado para o tratamento com CO 
inalado. Adicionalmente, a administração de CORM-2 inibe a agregação plaquetária e a 
perda de deformabilidade eritrocitária durante a infecção. Estas observações são 
importantes porque durante a infecção o desequilíbrio do sistema de coagulação parece 
contribuir para a patogénese da MC e, por outro lado, a diminuição da deformabilidade 
eritrocitária representa um forte biomarcador de severidade em malária humana. O 
CORM-2 parece contribuir assim para o restabelecimento do equilíbrio hemostático no 
modelo C57BL/6-PbA de CM, e, deste modo, para o não desenvolvimento da MCE. 
Contrariamente ao que se observa com o CO inalado, o tratamento com CORM-2 
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mantém constante, durante os dias 5 e 8 após infecção, a percentagem de glóbulos 
vermelhos infectados. No entanto, a relevância desta observação para a protecção 
conferida pelo CORM-2 no desenvolvimento da MCE deverá ser melhor estudada em 
experiências futuras.  
 
No seu conjunto, estes resultados indicam que as CO-RMs podem representar uma 
nova classe de compostos com potencial terapêutico na protecção do hospedeiro contra 
o desenvolvimento da malária cerebral. 
 
Palavras-chave: 
Malária Cerebral, CO, CO-RMs, Plasmodium berghei ANKA, Sequestração de glóbulos 
vermelhos infectados 
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2. Abstract 
 
Malaria is a major infectious disease worldwide, causing ~1 million deaths each year due 
to severe complications, one of the most lethal being cerebral malaria (CM). Thereby, 
understanding CM pathogenesis is of vital importance for developing effective therapies 
against it.  
 
The experimental cerebral malaria (ECM) model of C57BL/6 mice infected with P. 
berghei ANKA (PbA) shares many similarities with human CM. However, whereas in 
humans a critical event is sequestration of Plasmodium-infected red blood cells (iRBCs) 
in the brain microvasculature, in rodents is mostly leukocyte sequestration that occurs. 
Thereby, the pathologic significance of iRBCs brain sequestration during ECM is 
controversial and remains to be clarified.  
 
Recently, it was shown that heme-oxygenase-1 (HO-1) plays a crucial role in protection 
against ECM, which appears to be mediated by carbon monoxide (CO) production, an 
end-product of its enzymatic activity. In fact, administration of CO by inhalation rescues 
all C57BL/6 PbA-infected mice from developing ECM.  
 
The present study shows that CO protection comprises the reduction of iRBC brain 
sequestration in infected mice, supporting the importance of this process in ECM 
pathogenesis and the relevance of C57BL/5 PbA-infected mouse model to study CM. 
Moreover, our results indicate that CO has a therapeutic potential as a molecule with 
anti-inflammatory and anti-chemotaxis effects.  
 
We also demonstrate that CORM-2, a CO-relasing molecule (CORM-2), mimics CO 
protection against ECM, suppressing neuroinflammation and parasite sequestration in 
the brain. Importantly, CORM-2 does not induce formation of carboxyhemoblogin, 
circumventing CO inhalation toxicity. Moreover, CORM-2 inhibits platelet aggregation 
and loss of RBC deformability, which likely contributes to prevent disease development. 
Additionally, CORM-2 also leads to an arrest in parasite load, which origin and relevance 
is not clear.  
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Altogether, these results indicate that CO-RMs seem to represent a novel class of drugs 
with therapeutic potential to protect the host from cerebral malaria.  
 
Key-words: 
Cerebral malaria, CO, CO-RMs, Plasmodium berghei ANKA, Sequestration of infected 
red blood cells 
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3. Introduction 
 
3.1. Malaria: a worldwide burden 
Malaria is one of the most important infectious diseases worldwide, affecting ~200-300 
million individuals each year, over more that 100 countries, principally in sub-Saharan 
Africa (Fig. 1) (1). Along with the serious health problem, malaria has devastating 
economic consequences, standing as a main cause of poverty in many affected 
countries (2). Although most malaria infections only manifest as a relatively benign 
febrile illness, in 
many cases severe 
complications can 
arise from the 
disease, leading to 
nearly 1 million 
deaths every year, 
mainly among non-
immune children 
under 5 years of 
age (1). Severe 
malaria comprises 
several clinical 
manifestations such as cerebral malaria, severe anemia, hypoglycemia and acute 
respiratory distress, often occurring in combination within the same patient (3). 
  
3.2. Plasmodium life cycle in the mammalian host 
Malaria infection is caused by apicomplexan protozoa of the genus Plasmodium. The 
parasites have a complex life cycle that requires two hosts: a mosquito vector and a 
vertebrate host, which can be a mammalian, a bird or a lizard, depending on the 
Plasmodium species. There are five parasite species reported to infect humans, namely 
P. falciparum, P. vivax, P. malariae, P. ovale and, most recently, P. knowlesi (4). P. 
falciparum is by far the most widespread and dangerous of all parasites, standing as the 
major responsible for severe illness and mortality associated with malaria (1, 3). The 
entire life cycle as well as the morphology of the different developmental stages is 
Figure 1 Estimated incidence of malaria per 1000 population, on 2006 (adapted 
from WHO, 2008, ref. 1) 
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conserved between mammalian parasites, including those infecting rodents, namely P. 
berghei, P. chabaudi, P. yoelli and P. vinckei, which have been extensively used in 
experimental malaria models. 
 
3.2.1. Liver stage - The exo-erythrocytic cycle 
Malaria parasites are transmitted to a mammalian host trough the bite of a female 
Anopheles spp. mosquito during a blood meal, inoculating the first infective form of the 
parasite, the sporozoite, into the host dermis. Further on, sporozoites move from the skin 
and enter the blood circulation, travelling readily to the liver where they will initiate 
asexual replication. In the liver, the sporozoites transverse several hepatocytes before 
invading and developing in a final hepatocyte. Between 2 to 6 days later, according to 
the Plasmodium species (for human Plasmodium species from 6-16 days later), the 
infected hepatocytes rupture and thousands of merozoites per invading sporozoite are 
released into the bloodstream. This stage is the so-called liver stage of the parasite and 
is totally asymptomatic (Fig. 2) (reviewed in ref. 5). 
 
 
Figure 2 Plasmodium life cycle in the human host (adapted from an image from Malaria Unit at Instituto de 
Medicina Molecular) 
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3.2.2. Blood stage - The intra-erythrocytic cycle 
In contrast to the clinically silent liver stage, the blood stage of infection is when the 
malaria-associated pathology occurs. Each merozoite released from the liver invades a 
red blood cell (RBC) where asexually replicates during 24-72h, depending on the 
Plasmodium species (human Plasmodium species have a replication cycle of 48-72h), to 
produce merozoites. The replication cycle ends with the burst of infected RBCs (iRBCs) 
and the release of merozoites, which in turn will infect other RBCs and initiate a new 
cycle of asexual replication (Fig. 2) (reviewed in ref. 6). The typical waves of fever and 
chills observed during a malaria infection correspond to the cycles of erythrocyte rupture 
and re-infection by the parasites. Some Plasmodium species show a preference for 
invading reticulocytes, i.e. immature RBCs, whether others invade both mature RBCs 
and reticulocytes. In humans, P. 
vivax and P. ovale predominantly 
infect reticulocytes, as well as P. 
berghei and P. yoelli in rodents. 
During the asexual intra-erythrocytic 
cycle, parasites mature through 
several developmental stages. 
Inside the RBC, the parasite first 
establishes as a ring-stage, 
surrounded by a vacuolar membrane 
(parasitophorous vacuolar 
membrane) created from the 
invagination of the RBC plasma 
membrane that occurs during the invasion step. The ring-stage is characterized by a 
large vacuole where hemoglobin starts to be digested to form hemozoin or the so-called 
“malarial pigment”, the characteristic brown pigment of Plasmodium. Parasites feed on 
host RBC hemoglobin to obtain free amino acids and iron. However, digestion generates 
a noxious by-product, the free heme. To overcome heme toxicity the parasite converts it 
into hemozoin, which is an inert crystal (7). The young ring parasite further grows into a 
trophozoite, which displays a different shape and a larger cell size, and where DNA 
replication begins. Next, the parasite enters the schizont stage where nuclear division 
occurs. During schizogony the parasite replicates its DNA and divides its nuclei several 
times, forming a syncytial cell. Finally, as the schizont matures, cytoplasm divides, the 
Figure 3 Asexual blood stages of Plasmodium falciparum 
(adapted from Coatney, G.R. et al. 1971, ref. 10). 
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red blood cell rupture and 16 to 32 merozoites egress to invade fresh erythrocytes and 
perpetuate the cycle (Fig. 3) (reviewed in ref. 8, 9).  
 
3.2.3. Sexual stage  
The sexual life cycle of Plasmodium proceeds when 
some merozoites invade RBCs and undergo sexual 
differentiation (in response to stress or other stimuli) into 
gametocytes (Fig. 4), which can be taken up by 
mosquitoes during a blood meal. In the mosquito midgut, 
where fertilization occurs, the gametocytes fuse to 
produce a zygote denominated ookinete that develops 
into an oocyst in which thousands of sporozoites are 
formed.     Finally, the sporozoites migrate into the 
mosquito’s salivary glands where they remain ready to 
be transmitted (Fig. 2) (reviewed in ref. 6). 
 
3.3. Cerebral malaria (CM)  
Cerebral malaria is the most severe neurological complication and one of the most life-
threatening occurring from Plasmodium falciparum infection. CM affects mainly children 
and manifests clinically as motor and behaviour abnormalities, fever, consciousness 
impairment, convulsions and coma, ultimately leading to neurological sequelae or death 
(3). The usual treatment with anti-malaria drugs, like quinine and artemisin derivatives, is 
not sufficient to rescue CM patients from death or cognitive deficits. Along with anti-
parasitic therapy, the patients of cerebral malaria must receive supportive treatment, 
such as exchange transfusion, ventilation support, treatment of renal failure, correction 
of acid-base imbalance and administration of anti-convulsants.These treatments are not 
always easily available in the sub-developed countries where malaria is endemic. Other 
adjunctive treatments have been suggested however none of them have shown proved 
benefits and some are reported as deleterious (reviewed in ref. 11, 12). Regardless of 
the efforts to improve CM treatment, there is still no successful therapy and the disease 
continues to exhibit high mortality and morbidity rates. The threat of this health problem 
is underlined by the observation that in endemic areas ~ 20% of children suffering from 
CM still succumb to the disease (13). A clear understanding of the mechanisms 
underlying CM pathogenesis is hampered by the complexity and multi-factorial 
Figure 4 Sexual blood stages of 
Plasmodium falciparum 
(adapted from Coatney, G.R. et 
al. 1971, ref. 10). 
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dependence of the pathology. Besides the parasite transmission, virulence and drug 
resistance characteristics, many nutritional, genetic and immunological host factors have 
been implicated in the disease (14). In this way, despite the important insights already 
provided, many aspects underlying CM etiology remain unclear and subject of debate. 
Novel studies are crucial to shed light on the pathogenic mechanisms behind it and 
improve our knowledge of the disease in order to develop new therapeutic strategies 
that effectively combat it. 
 
3.4. Experimental cerebral malaria (ECM): the benefit of rodent models 
Studying CM pathology in humans is obviously not simple. Many of the studies rely on 
post-mortem analyses which do not provide insights into the full pathogenic events 
leading to the disease and hinder a direct correlation with clinical symptoms. Besides, 
the presence of other severe malaria complications or non-malaria pathologies often 
brings difficulties to the correct diagnosis of CM and the establishment of CM-specific 
associations. Therefore, experimental animal and in vitro models have been invaluable 
tools to study this pathology (reviewed in ref. 15). The most widely used and best 
characterized animal model of experimental cerebral malaria (ECM) is Plasmodium 
berghei ANKA (PbA) infection in C57BL/6 mice. In this ECM model 80-100% of C57BL/6 
mice develop neurological signs identical to human CM (mono-, hemi-, para- ou 
tetraplegia, tendency to roll over on stimulation, ataxia, convulsions and coma) and die 
between days 6 and 12 after inoculation with P. berghei ANKA iRBCs. Parasitemia, the 
percentage of iRBCs in circulation, is generally low at the time of death. ECM resistant 
strains of mice such as BALB/c mice are also used for comparative purposes. Only 0 to 
20% of BALB/c mice infected with the same dose of P .berghei ANKA iRBCs develop 
ECM while the remaining BALB/c mice die 2 to 3 weeks after infection with severe 
anemia and hyperparasitemia but without neurological signs (16, 17).  
The ECM model of C57BL/6 mice infected with P. berghei ANKA shares many 
similarities with the human pathology, including the referred neurological symptoms, 
development of brain petechial hemorrhages, edema, disruption of blood-brain barrier 
(BBB), systemic increase of pro-inflammatory cytokines, up-regulation of adhesion 
molecules in the brain endothelium, changes in the brain metabolism and establishment 
of a pro-coagulant state (18-20). The main distinction argued between the mouse and 
human CM is that whereas in humans are mainly iRBCs that sequester in the brain 
microvasculature and that this is a key event for the human disease, in rodents is mostly 
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leukocyte sequestration that takes place. Hence, the pathologic importance of iRBCs 
sequestration in the brain vasculature during ECM has long been a matter of controversy 
and remains to be clarified. This issue will be discussed further on. 
 
3.5. Pathogenesis of CM: sequestration, inflammation and hemostasis dysfunction 
Until know there are three main hypothesis to explain CM pathogenesis: the 
sequestration (or mechanical), the inflammation and the hemostasis hypothesis. 
Currently, it is accepted that these three main processes do not act independently in the 
development of CM but there is an intricate interplay between them, responsible for the 
complexity of the disease (21).  
 
3.5.1. Sequestration of iRBCs 
Since the first studies about severe malaria that the presence of infected and uninfected 
sequestered RBCs in the microvasculature of organs such as brain, heart, lungs, liver, 
kidney, spleen, intestines, adipose tissue and placenta has been a persistent histological 
finding in patients suffering from severe pathology (22-24). Given the constancy of this 
observation, erythrocyte sequestration is generally accepted as a hallmark and crucial 
event for the pathogenesis of severe malaria. The distribution of parasite sequestration 
in the organs varies and tends to reflect the clinical outcome of disease. Indeed, it has 
been reported that patients with CM show an increased RBC sequestration in the brain 
microvasculature, when compared with other organs (25). Sequestration of both non-
infected and infected RBCs at later erythrocytic developmental stages, namely mature 
trophozoites and schizonts (22), occurs possibly via different possible mechanisms. The 
sequestration hypothesis, proposed as early as 1894 by Marchiafava and Bignami (26), 
establishes sequestration as the primary cause of severe malaria. According to it, the 
cytoadherence of iRBCs to endothelial cells (ECs) of capillaries and post-capillary 
venules results in blood flow obstruction that leads to petechial hemorrhages, metabolic 
dysfunction, hypoxia and deficient removal of waste products, such as lactate, giving rise 
to disease (reviewed in 27). In one hand, the iRBCs might adhere to the ECs via P. 
falciparum proteins expressed at the erythrocyte surface, principally through P. 
falciparum erythrocyte membrane protein-1 (PfEMP-1) (28). Antigenic variability of 
PfEMP-1 molecules is a major mechanism used by the parasite to evade host immune 
responses (reviewed in 29). PfEMP-1 binds to receptors up-regulated during infection in 
the host vascular endothelium, namely intercellular adhesion molecule-1 (ICAM-1), 
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vascular adhesion molecule-1 (VCAM-1), CD36, E-selectin, P-selectin, thrombospondin 
(TSP) or chondroitin sulphate A (CSA) carbohydrates, the last one particularly 
associated with placental malaria (reviewed in ref. 30, 31). On the other hand, 
sequestration can be amplified through the adhesion of iRBCs to other iRBCs 
(autoagglutination) or to non-infected RBCs (rosetting), or through platelets bound to 
iRBCs (platelet-mediated clumping) (32, 33). In addition to the iRBCs cytoadherence 
capacity, during a P. falciparum infection both infected and uninfected RBCs become 
less deformable (34) and consequently exhibit a higher tendency to plug vessels, further 
contributing to microcirculation obstruction (35). Cytoadherence of iRBCs is a process 
thought to confer survival advantage to parasite by providing a microaerophilic venous 
environment that is better suited for its maturation and by escaping clearance by the 
spleen, which recognizes iRBCs loss of deformability (34, 36) and opsonisation with 
antibodies and/or complement components (37). 
 
3.5.2. Sequestration of iRBCs in the murine model 
As stated before it is still a mater of debate whether the murine model closely resembles 
the pathogenesis of human CM, particularly in what concerns iRBCs sequestration in the 
brain microvasculature, a hallmark of CM. The sequestration phenomena appear to be a 
common denominator in human and murine CM, although the main cell type 
sequestered in the host organs differs between human and murine pathology. It has 
been shown that parasitized RBCs accumulate in the brains of different CM-susceptible 
mouse strains infected with P.berghei ANKA at the time of neurological symptoms (38-
41). Nevertheless, leukocytes are the principal cell type consistently found to sequester 
in the mouse (38, 39, 42, 43) rather than iRBCs, as seen in humans (22). Given this fact, 
the pathological relevance of iRBC sequestration in the murine model has been 
discussed. Recently, Frank-Fayard and colleagues have investigated iRBCs 
sequestration in the C57BL/6 murine model making use of a real-time in vivo imaging 
system and a transgenic luciferase-expressing P. berghei ANKA parasite. The work 
indicates that iRBC sequestration in mice is largely mediated by CD36, and occurs 
mainly in the lungs but also in the adipose tissue, however is negligible in the brain. The 
study also shows that parasite sequestration does not appear to correlate with pathology 
since CD36-/- mice develop ECM (44). On the contrary, other studies using the same 
mouse model and imaging system show an association between cerebral pathology and 
increased iRBCs accumulation in the brain (45, 46). Also, quantitative PCR data 
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suggests that significantly higher numbers of P. berghei ANKA parasites sequester in 
the brain and other organs of ECM-susceptible mice, when compared with the organs of 
resistant mice (15). Moreover, a very recent work by Baptista et al. strongly sustains that 
the concomitant presence of iRBCs and CD8+ T lymphocytes are a prerequisite for ECM 
onset in P. berghei ANKA-infected mice (47, submitted). CD8+ T cells are key mediators 
of ECM that will be considered in more detail further on. Nevertheless there is still no 
consensus, in the malaria research field, about the relevance of PbA iRBCs 
sequestration in ECM. Other parasite species and mouse strains have been suggested 
as alternative models to study iRBCs sequestration, although none of them shares as 
many similarities with human CM as the PbA infection in C57BL/6 mice model. One 
example is the lethal (17XL) strain of P. yoelli which induces ECM in Swiss mice. In this 
model, a prominent intravascular sequestration of iRBCs occurs but with few or any 
leukocyte accumulation in the brain, resembling human CM histopathology. However, 
this strain causes a virulent infection that gives rise to very high levels of parasitemia 
(48). Also, P. chabaudi AS iRBCs exhibit a significant cytoadherent capacity, 
sequestrating mainly in the liver and to a lesser extent in the spleen and brain of CBA 
mice. Nonetheless, the P. chaubadi AS infection self-resolves and do not develop into 
severe disease (49). 
In fact, although iRBCs sequestration is widely accepted as a key feature of human CM, 
it has become evident that alone can not explain the pathogenesis of the disease. The 
sequestration process during P. falciparum is a common event in patients with severe 
illness or asymptomatic malaria. For this reason parasite sequestration in the tissues is 
not sufficient to induce a specific pathology (13).  Indeed, some studies defend that brain 
sequestration does not occur in all patients who have succumbed from clinically 
diagnosed CM (50, 51) and, similarly to what is observed in mouse models, brain 
intravascular infiltrates with leukocytes and platelets have also been associated with 
human cerebral pathology (52-55). These findings approach mouse and human 
pathology and suggest other mechanisms underlying CM pathology apart from RBC 
sequestration.  
 
3.5.3. Inflammation 
Now, it is generally accepted that host immune responses also play an essential role in 
the malaria-associated pathology. According to the inflammation theory, the 
inflammatory processes triggered by infection are important for parasite control and 
 16 
clearance; however, the immune system might set up an exacerbated inflammatory 
response that leads to multi-organ failure and death (reviewed in ref. 56). The 
inflammatory cascade is complex, probably including different players of the innate and 
adaptive immune system and the sequence of events is still far from being completely 
elucidated. Studies have been focused on identifying the crucial regulators of the 
inflammatory state responsible for CM pathology. These include pro-inflammatory 
cytokines such as tumour necrosis factor-α (TNF-α), lymphotoxin-α (LT-α) and 
interferon-γ (IFN-γ), cellular adhesion molecules, like ICAM-1, and T lymphocytes, 
particularly CD8+ T lymphocytes, which have been closely associated with the 
pathogenesis of the disease and used as markers of murine cerebral pathology 
(reviewed in ref. 57). 
 
3.5.3.1. Pro-inflammatory cytokines: tumor necrosis factor-α (TNF-α), 
lymphotoxin-α (LT-α) and interferon-γ (IFN-γ) 
TNF-α is generally considered an essential element in the immunopathogenesis of CM. 
Increased levels of the cytokine in circulation and brain expression have been commonly 
associated with human and murine pathology (58-61). In the CBA murine model of CM, 
depletion of the cytokine prevents development of the disease (42). However, the 
abrogation of ECM development in TNF-α-LT-α double gene-knockout mice not only 
supports a role for TNF-α but also for LT-α, a molecule related to TNF-α family, in the 
pathogenesis of CM (62). In fact, LT-α -/- mice infected with PbA were shown to be 
completely protected against ECM whereas TNF-α -/- showed the same incidence of 
ECM as control C57BL/6 wild-type mice, suggesting that LT-α, and not TNF-α, is a 
principal cytokine mediator of pathology in this murine model (63). TNF receptor 2 
(TNFR2) also appears crucial for the pathogenesis of the disease since TNFR2 -/- mice 
are significantly resistant to ECM development. The central role of TNFR2 would 
probably lie on the shared usage of this receptor by TNF-α and LT-α (64). Recently, also 
LT-α signalling mediated by lymphotoxin-β receptor (LTβR) has been shown to be an 
essential pathway in ECM (65, 66). 
Other pro-inflammatory cytokine, IFN-γ, has been considered a key mediator in CM 
pathogenesis. Elevated concentrations of IFN-γ are also observed in circulation during 
human acute malaria (67, 68) and a recent study reports that heterozygotes for an IFN-γ 
receptor (IFN-γR) polymorphism had lower incidence and mortality from CM (69). The 
central role of IFN-γ in the cerebral pathology is strongly corroborated in the murine 
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model in which depletion or deficiency for IFN-γ or its receptor totally prevents disease 
onset (70, 71).  
 
3.5.3.2. Leukocyte accumulation in the brain: the importance of CD8+ T cells  
As aforementioned, brain accumulation of leukocytes occurs in both murine and human 
CM although leukocytes accumulate more than RBCs in the murine model. During ECM, 
brain intravascular leukocytes are mainly constituted of monocytes/macrophages, 
neutrophils and T lymphocytes (38, 39, 41, 72). Several studies using neutralising 
antibodies and T-cell deficient mice, demonstrated the requirement of CD4+ and CD8+ T 
cells for the cerebral pathology of P. berghei ANKA-infected mice, among which CD8+ T 
cells were proved to play a central role (71-77). There is a selective increase in brain 
CD8+ T cells in mice that developed ECM compared with mice that do not develop ECM. 
Moreover antibody depletion of CD8+ T cells on the day before the development of 
neurological symptoms totally abrogates ECM (72, 74). The crucial involvement of CD8+ 
T cells as direct effectors in ECM pathology is further supported by the observation that 
their recruitment to the brain just precedes the onset of neurological signs, 
demonstrating their pivotal role on the late stages of the disease (78). These results 
were corroborated by adoptive transfer experiments where spleen CD8+ T cells, since 
the spleen is the main organ of CD8+ T cell activation, of mice with ECM, adoptively 
transferred to T-cell deficient mice (RAG-2 deficient mice) were found to migrate to the 
brain and lead to ECM (76). CD8+ T cells are essential effector cells of the adaptive 
immune system directed for killing of cells invaded by pathogens or malignant cells. Still, 
these cells have to be tightly regulated in a way to prevent immunopathogenesis.  Thus, 
CD8+ T cell-mediated apoptosis of neurovascular ECs and consequent BBB damage is 
thought to underlie the role of these cells during ECM (78). Granzyme B and perforin are 
molecules produced by activated CD8+ T cells that mediate their cytotoxic action by 
inducing apoptosis through caspase activation. The pathogenic significance of EC killing 
by activated CD8+ T cells is strongly supported by the observation that these molecules 
are highly up-regulated in the brain during ECM and that perforin-deficient mice do not 
develop the pathology (76, 78, 80). Of special importance is a recent work showing that, 
albeit the importance of CD8+ T cells in ECM pathology, these cells are not sufficient per 
se to induce ECM unless iRBCs are also present in the brain microvasculature. Thereby, 
the simultaneous recruitment of both cells to the brain is required for the murine cerebral 
pathology to occur (47, submitted). As mentioned before, also CD4+
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shown to participate in ECM pathogenesis of P. berghei ANKA-infected mice. However, 
these cells seem to be involved at an induction phase of the disease rather than exerting 
a direct action as CD8+ T cells (72, 73, 75). Besides T lymphocytes, also 
monocytes/macrophages and neutrophils accumulate in the brain microvasculature 
during ECM. These phagocytic cells are part of the innate immune response and seem 
more implicated in the early establishment and amplification of the inflammatory state, 
both systemically and locally in the brain, by producing high levels of pro-inflammatory 
cytokines, such as IFN-γ and TNF-α, and secreting chemokines, i.e. chemotactic 
molecules that trigger leukocyte migration, like CC ligand-5 (CCL5), IFN-γ-inducible 
protein-10 (IP-10) and monokine induced by IFN-γ (MIG). Indeed, depletion of 
macrophages or neutrophils early in infection prevents the development of ECM, down-
regulating the expression of pro-inflammatory cytokines in the brain and markedly 
decreasing the sequestration of leukocytes (81, 82).  
In fact, due to their chemotaxis function of leukocytes, chemokines have been 
investigated as possible mediators in CM pathogenesis. Mice deficient in the CC 
chemokine receptor-5 (CCR5), the receptor of CCL5, have been reported to be 
significantly resistant against ECM development or exhibit a delayed onset of the 
pathology, probably due to impaired CD8+ T cell trafficking to the brain (76, 83). Recent 
studies have drawn more attention over CXC chemokine receptor-3 (CXCR3) and its 
ligands IP-10 and MIG. These chemokines are up-regulated in response to PbA infection 
and mice knock-out for CXC3, IP-10 or MIG genes are significantly protected against 
disease, clearly implicating these molecules on ECM pathogenesis Moreover, splenic T 
cells from CM susceptible mice but not resistant mice, induce the expression of CXCR3, 
indicating a correlation between CXCR3 expression and disease. In fact, the pathogenic 
contribute of CXCR3 during ECM was correlated with lymphocyte recruitment since 
CXCR3 deficient mice show a marked impairment of CD8+ T cell migration to the brain 
(46, 84-86). Importantly, IP-10 was found to be a biomarker of CM-associated mortality 
in P. falciparum malaria (87, 88). These studies suggest that chemotactic factors such 
as IP-10, and their respective receptors, play an important role in cerebral pathogenesis, 
at least in part by mediating CD8+ T cell trafficking to the brain. 
 
3.5.3.3. Adhesion molecules: intercellular adhesion molecule-1 (ICAM-1) 
Other key event that appears crucial to CM pathogenesis is the stimulation of a pro-
adhesive phenotype in the vascular endothelium, through up-regulation of adhesion 
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molecules. Pro-inflammatory cytokines such as TNF-α, LT-α and IFN-γ, induced during 
infection, can activate the vascular endothelium inducing the expression of adhesion 
molecules such as ICAM-1, VCAM-1 and P-selectin This in turn promotes sequestration 
of parasitized erythrocytes and leukocytes to brain microvasculature, which likely 
contributes to neurovascular endothelial damage and BBB derangement (65, 71, 89, 
90). ICAM-1 has been an adhesion molecule strongly associated with CM pathogenesis. 
An high up-regulation of the molecule in the brain correlates with cerebral pathology in 
humans and rodents (91-93) and ICAM-1-/- mice were shown to be fully protected 
against the pathology (94).  
 
3.5.4. Hemostasis dysregulation 
Besides iRBC sequestration and inflammation, dysfunction of hemostasis system is 
another process argued to significantly contribute to CM pathogenesis. Supporting this 
hypothesis is the persistent observation that patients suffering from P. falciparum 
malaria exhibit dysregulation of the coagulation system including prolonged bleeding 
times and prothrombin times, decreased levels of anti-coagulants, platelet 
hyperaggregability, thrombocytopenia (low levels of circulating platelets), generation of 
pro-coagulant microparticles and occurrence of microthrombi and haemorrhages in brain 
vessels (95, 96). Several evidences during murine and human CM indicate an important 
role for platelets, major players of the hemostasis system, in the microvascular injury 
occurring during pathology (reviewed in ref. 97). Platelets can cooperate with iRBC to 
amplify sequestration by mediating iRBCs clumping, i.e. aggregation, and iRBCs 
adhesion to brain endothelium (33, 98). As a consequence, vascular obstruction and 
damage to brain ECs would be enhanced. In fact, the thrombocytopenia observed during 
severe malaria and particularly in CM is hypothesized to be a host protective mechanism 
against platelet-mediated clumping of iRBCs (99). On the other hand, platelets are also 
immune effector cells, that could augment the pro-inflammatory environment associated 
with CM. A recent study supporting such an immuno-modulatory role for platelets during 
pathology, demonstrates that platelet activation by iRBCs induces the production of 
platelet factor 4 (PF4), a platelet-derived chemokine, which acts as an important immune 
activator and mediator of T cell recruitment to the brain during ECM (100). In addition, 
microparticles, other elements of the hemostasis system, have been suggested as 
relevant effectors in the pathogenesis of the disease. Microparticles are submicrometer 
elements resulting from the shedding of the plasma membrane from various cell types, 
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which circulate in the peripheral blood and have been implicated in thrombosis, 
inflammation and vascular activation (20, 101).  
 
3.5.5. The integration of events: blood-brain barrier (BBB) damage 
The integrated action of the pathogenic mechanisms of sequestration, inflammation and 
hemostasis deregulation is generally accepted to culminate in the dysfunction and, 
ultimately the breakdown of BBB, during both murine and human CM (39, 102, 103). 
BBB is a highly specialised interface between the intravascular space and the central 
nervous system that function as a selective diffusion barrier which tightly controls 
molecular and cellular trafficking into the brain, maintaining homeostasis. The structural 
and functional integrity of BBB depends on endothelial cells (ECs) with characteristic 
tight and adherens cell junctions, astrocytes, pericytes, perivascular macrophages, 
neurons and microglia i.e. resident macrophages in the brain (104). During cerebral 
pathology, activation of microglia, damage and apoptosis of astrocytes appear as crucial 
events in BBB disruption (105-109). Moreover, injury and apoptosis of microvasculature 
ECs were also implicated in the BBB damage, and associated with CD8+ T cell perforin-
mediated cytotoxicity, as already mentioned (76, 79, 80, 110). Additionally, CD8+ T cells 
can also impair BBB tight junctions without inducing apoptosis, though in a perforin-
dependent manner (111). Furthermore, neuronal apoptosis, which is observed during 
ECM, is likely to play a role in human CM and mediate the irreversible neurological 
sequelae that can occur in non-lethal CM cases (112, 113). 
In summary, although the precise sequence of events leading to CM is unknown, we 
know now many events involved in the pathology that allow us a more extended view of 
the mechanisms that lead to CM. The comprehensive knowledge of these processes is 
fundamental to discover new drug targets and develop novel treatment strategies 
against the pathology. Scientific work has made evident the involvement of different host 
factors in the progression of CM and keeps extending the range of cells and host 
molecules implicated either in pathogenesis or protection against the disease. In this 
way, recently, heme-oxygenase-1 (HO-1) and carbon monoxide (CO), one of its 
products, were identified as molecules playing a critical role in the host protection 
against CM in mice (114). 
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3.6. Heme-oxygenase-1 (HO-1) and carbon monoxide (CO) 
Heme-oxygenase (HO) is the rate limiting enzyme in the catabolism of free heme (iron 
protophorphyrin IX). HO breaks down the porphyrin ring of heme rendering equimolar 
amounts of biliverdin, free iron (Fe2+) and carbon monoxide (CO) (115). In mammals, 
biliverdin is rapidly converted by biliverdin reductase into bilirubin (116). Heme is a 
prosthetic group of many proteins, for this reason called hemoproteins, such as 
hemoglobin (Hb), cytochromes, peroxidases (117), as well as cyclooxygenase-2 (COX-
2) (118), inducible nitric oxide synthase (iNOS) (119) and indoleamine 2,3-dioxygenase 
(IDO) (120), which are likely implicated in host protective response against severe 
malaria. Besides, heme is also directly involved in many cellular processes such as gene 
modulation, cell differentiation, cell proliferation and immune stimulation. However, when 
excessive concentrations of heme are present in the free state, this leads to oxidative 
damage of cells and tissues (reviewed in 117). Three isoforms of HO enzyme have been 
identified, respectively HO-1, HO-2 and HO-3, codified by different genes with different 
expression patterns. While HO-3 expression profile is still not characterized, HO-2 
expresses constitutively and HO-1 expression is inducible (121, 122). HO-1 expression 
is up-regulated as part of the host protective response against stress conditions, and can 
be triggered by a wide range of agents particularly those that increase oxidative stress 
such as heavy metals, bacterial lipopolysaccharides (LPS), hypoxia, hyperoxia, heat 
shock, ischemia, UV radiation, H2O2, cytokines, nitric oxide (NO), and its substrate 
heme. HO-1 not only plays a role in important biological functions such as vasodilatation 
and neurotransmission, but also exerts a remarkable cytoprotective action in different 
pathological conditions due to its anti-inflammatory, anti-apoptotic, anti-oxidative and 
anti-proliferative effects. Such activities result both from degradation of excessive free 
heme by the enzyme and from the biological actions of the three products generated 
(reviewed in ref. 123). From these products, CO is the best studied and the one that 
more closely mimics HO-1 effects when administered exogenously, sustaining the notion 
that HO-1 protective actions are principally mediated by CO production (117). The 
biological significance of the molecule is reinforced by the observation that CO functions 
as a signalling mediator in important physiological processes such as vasorelaxation and 
neurotransmission (124). Similarly to HO-1, CO anti-apoptotic, anti-proliferative, anti-
oxidative and anti-inflammatory properties and capacity to inhibit platelet aggregation 
have been associated with its ability to ameliorate cardiac, lung, liver and vascular 
injuries, including protection against experimental allo- and xenotransplantation 
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rejection, oxidative damage, ischemic injury, thrombosis and sepsis (125-134). Although 
the direct molecular targets of CO responsible for its bioactivity remain to be indentified, 
its effects are known to be mediated by at least two major pathways: the soluble 
guanylate cyclase (sGC)/cyclic guanosine monophosphate (cGMP) system and mitogen-
activated protein kinases (MAPKs) (123). Other molecules seem to be involved in CO 
signalling like stress-responsive transcription factors including nuclear factor κ-light-
chain-enhancer of activated B cells (NF-κB), peroxisome proliferator-activated receptor-γ 
(PPAR-γ) and hypoxia-inducible factor-1α (HIF-1α). Also, the affinity of CO for metal 
atoms supports that metalloproteins could act as CO biological sensors, in particular 
heme-containing proteins such as hemoglobin, myoglobin, sGC, COX-2, cytochromes, 
iNOS and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (123, 124). 
Recently, also CO-induced production of reactive oxygen species (ROS) has been 
defended to mediate CO signalling (135). The CO pleiotropic effects thus rely on 
modulation of different pathways, depending on tissue and cell types and the biological 
effect exerted.  
 
3.6.1. Pivotal role of HO-1 and CO in the protection against ECM 
Reinforcing the function of HO-1/CO system as a host defence against pathological 
conditions, a recent work by Pamplona and colleagues (114), revealed that HO-1 plays a 
crucial role in the control of CM progression in P.berghei ANKA-infected mice. Upon 
infection, the enzyme is up-regulated at lower levels in the ECM-susceptible strain of 
C57BL/6 mice, which develop ECM, compared with the ECM-resistant strain of BALB/c 
mice that do not develop the pathology. The involvement of HO-1 in the susceptibility to 
ECM was further corroborated by showing that BALB/c resistance to disease was lost by 
the majority of mice due to inhibition of HO-1 activity or HO-1 deficiency. HO-1 protective 
effect appears to be mediated by CO production since exogenous administration of CO, 
by inhalation, rescues 100% of C57BL/6 infected mice from developing ECM, whereas 
biliverdin treatment failed to do so. The protection against ECM development conferred 
by HO-1 induction and CO exposure was not related with parasitemia alterations, but 
rather with abolishment of brain microvasculature congestion with leukocytes and RBCs, 
brain hemorrhages and prevention of BBB disruption. Importantly, the CO protective 
effect correlated with inhibition of neuroinflammation in the C57BL/6-infected mice, 
verified by reduction of brain expression of TNF-γ, LT-α, ICAM-1 and VCAM-1 and 
prevention of activated CD8+ T cell recruitment to the brain (114). The HO-1/CO 
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protective roles during ECM were shown to rely, at least in part, on reducing free heme 
in circulation. During a malaria infection extensive hemolysis occurs, due to rupture of 
iRBCs as a consequence of parasite replication, and to decreased life-span of 
uninfected RBCs (136). This originates the release of considerable amounts of 
hemoglobin (Hb) into circulation. In the presence of ROS, hemoglobin, HbFe2+, is readily 
oxidized to methemoglobin (MetHb), HbFe3+, which is highly unstable and promptly 
releases free heme. Thereby, the homeostasis of these molecules must be tightly 
regulated by the organism in order to protect cells and tissues from heme-induced 
inflammation and oxidative damage. Mammals possess several defense mechanisms to 
maintain Hb/MetHb/heme homeostasis including the RBC MetHb reductase system, 
HOs and the scavengers haptoglobin, hemopexin and albumin (137, 138). However, in 
situations of hemolysis, such as observed during a malaria infection, the physiological 
mechanisms of defence may become exhausted and insufficient to avoid excessive free 
heme release. In line with this, a significant increase in free heme in the plasma was 
shown to correlate with ECM onset in C57BL/5 PbA-infected mice, whereas BALB/c 
PbA-infected mice or C57BL/6 P.berghei NK65-infected mice, which do not developed 
ECM, had significantly lower levels of free heme in circulation (114). Moreover, CO 
protection against ECM was shown to be mediated by inhibition of free heme generation 
since C57BL/6 P. berghei ANKA- infected mice protected by CO exposure have reduced 
free heme in the plasma and, reversely, CO protection against ECM can be eliminated 
by heme administration in these mice. Importantly, it was also shown that MetHb plasm 
levels were significantly increased in ECM-developing C57BL/6 infected mice, while CO 
protected mice had MetHb levels similar to those observed in uninfected mice. 
Altogether, the results point towards an essential role of free heme in the pathogenesis 
of ECM. Moreover, the protective action of HO-1/CO system against pathology does not 
target the parasite but is hypothesized to result, at least partially, by preventing Hb 
oxidation to MetHb and subsequent heme release. This is probably attained through the 
CO binding to Hb, producing carboxyhemoglobin (COHb) (114, 138). Noteworthy, CO is 
also able to inhibit CD8+ T cell recruitment to the brain, preventing neuroinflammation 
and BBB disruption. The interdependence of these events is not established but 
together, they seem to underlie the protective action of CO against CM in the murine 
model (114). These results give an important contribution for the better understanding of 
CM pathogenesis, which could lead to the development of novel therapeutic strategies, 
possibly by targeting the Hb/MetHb/heme system. Moreover, an important implication 
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from these observations is the hypothesis that measurement of free heme or MetHb in 
the blood could serve as a prognostic tool of CM (138). Additionally, an interesting link 
between CO and NO, another gaseous endogenous messenger, could be drawn, 
supporting the involvement of cell-free Hb in CM pathogenesis. NO and CO share many 
similarities including vasodilation, neurotransmission, anti-inflammatory properties (139). 
Evidences suggesting a protective function of NO in CM further close the two molecules. 
Actually, despite the fact that NO is produced as part of the inflammatory response 
against the parasite, low, rather than high NO bioavailability is associated with human 
severe malaria and with ECM onset in the C57BL/6 PbA-infected mice (140, 141). 
Strikingly similar to CO, exogenous NO administration markedly protected mice against 
disease development, without changes in parasitemia, by decreasing pro-inflammatory 
markers in the blood, BBB permeability and brain hemorrhages (141). NO low 
bioavailability was presumed to result from hypoargininemia (deficiency in arginine, the 
substrate for NO synthesis by nitric oxide synthase, NOS), by low blood and RBC nitrite 
production and, importantly, by the increase of free Hb in the blood, which scavanges 
NO (141). What is more, a significant correlation between cell-free Hb, low NO 
bioavailability, endothelial dysfunction and inflammation was also established for severe 
malaria in humans (142). It is possible that CO, by binding to Hb, prevents NO 
scavenging and this in turn would lead to increased NO bioavailability, and thus 
contribute to suppression of ECM. On the other side, NO is a potent inducer of HO-1 and 
thereby its protective action against disease might be mediated by stimulating CO 
production (114). 
Besides prevention against ECM, HO-1/CO protective role was also demonstrated by 
our lab in another model of severe malaria. The P. berghei-ANKA-infected DBA/2 mice 
were shown to constitute a good model of malaria-associated acute respiratory distress 
syndrome (MARDS). During MARDS, lung injury is a central event, sharing 
histopathological similarities with BBB disruption during ECM, including increased 
permeability, hemorrhages and edema. Remarkably, HO-1 induction and CO exposure 
totally prevented MARDS incidence. Moreover, CO treatment blocked the increase in 
vascular endothelial growth factor (VEGF) in circulation, which appears crucial to the 
establishment of the respiratory syndrome (143, submitted). 
Interestingly, although HO-1 and its product CO, have a pivotal role in preventing 
malaria pathology during the blood stage of infection, a work by our lab revealed that the 
anti-inflammatory activity of HO-1 and CO promotes the liver stage of infection. In fact, 
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Plasmodium sporozoite infection on the liver induces HO-1 expression, which in turn 
down-regulates the inflammatory response, protecting the infected hepatocytes, and 
leading to increased parasite loads in the liver (144). This suggests that HO-1 
expression can play different regulatory roles during a malaria infection, depending on 
the tissue and parasite stage. 
Discovery of CO signalling properties surprised the scientific community and attracted 
attention for a molecule formerly regarded as physiological insignificant and an air 
pollutant. In fact, CO was best known for its strong toxicity when present in high 
concentrations, by virtue of CO ability to tightly bind to the heme-dependent proteins 
haemoglobin (forming COHb), myoglobin and cytochromes, blocking oxygen delivery 
and leading to tissue hypoxia, ultimately causing death (145). However, it should be 
underlined that CO beneficial effects have been experimentally obtained in mice at 
concentrations (250 p.p.m, parts per million) far below its toxic levels (123).  
In this way, while more studies to disclose the CO protective mechanisms are 
imperative, namely in the context of protection against severe malaria, a potential 
application of CO as a therapeutic agent, at low doses, has being increasingly predicted. 
 
3.7. CO-releasing molecules (CO-RMs) 
Indeed, the discovery that CO plays a significant role in life processes together with the 
observation that exogenous administration of CO gas could mimic the cytoprotective 
effects induced by HO-1 stimulation, prompted scientists to search for strategies aiming 
at CO application as a pharmacological agent. Major problems emerging from the 
potential use of CO gas therapy are the dangerous effects associated with its toxicity 
besides the fact that CO cellular targets responsible for its cytoprotective effects are still 
poorly known. Recently, to overcome these problems, the majority of research has been 
dedicated to the so-called CO-releasing molecules (CO-RMs), i.e. molecules that could 
carry and deliver CO in a more specific and controllable manner to cells and tissues, 
exerting the same protective effects of gaseous CO but overcoming CO toxicity. On the 
other hand, due to their more specific CO release, for instance through ligand 
substitution, these compounds would serve as important tools to identify the intracellular 
targets of CO and clarify the mechanism responsible for its bioactivity (148).  
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3.7.1. CO-releasing molecule-2 (CORM-2): vasorelaxing, anti-proliferative, anti-
ischaemic, anti-oxidant and anti-inflammatory properties 
Transition metal carbonyl complexes, 
constituted by CO groups bounded to a 
transition metal centre, have been emerging as 
promising CO-releasing molecules (CO-RMs) 
(149), mimicking CO beneficial effects in 
different experimental models of pathology 
(148, 150). CO-releasing molecule-2 (CORM-2) 
i.e. tricarbonyldichlororuthenium (II) dimer 
([Ru(CO)3Cl2]2) is one of the compounds most 
studied. This molecule is constituted by two 
monomers, each with a ruthenium centre bounded to three carbonyl groups, linked by 
two chlorine atoms. CORM-2 only solubilises on organic solvents, and dimethyl sulfoxide 
(DMSO) has been the usual vehicle used to test the compound. During solubilisation, 
DMSO acts as a coordinated ligand to ruthenium, consequently promoting the 
separation of the monomers and CO liberation (151). Usually, the CO-dependent activity 
of CORM-2 is validated by comparison with the negative control compound, at equimolar 
concentrations. This compound contains a similar ruthenium centre but the does not 
contain carbonyl groups and thereby cannot release CO. In the first study characterizing 
CO-RMs properties, namely that of CORM-2, it was shown in vitro that the compound 
dissolved in DMSO acts as a fast CO-releaser (half-life ≈ 1 min.) once in contact with 
heme-dependent proteins such as myoglobin. CO dissociation occurs by ligand 
substitution triggered by heme-iron, to which CO has strong affinity. Indeed, CORM-2 
rapidly converts deoxymyoglobin to carbonmonoxy myoglobin, implying that CO is 
effectively liberated from the metal complex. CO liberation is concentration-dependent, 
each mole of CORM-2 solubilised in DMSO being estimated to release approximately 
0.7 moles of CO (151). The study also assessed the biological properties of the 
compound, demonstrating in ex-vivo rat aortae that CORM-2 exerts a potent vasodilator 
activity and, in accordance, significantly attenuates acute hypertension in vivo in the rat 
model. Importantly, the fact that the negative control compound failed to promote the 
same vasorelaxing effects, sustained the involvement of CO in the bioactivity of CORM-
2. The vasodilator action was mediated by activation of sGC)/cGMP pathway, thus 
reproducing the vasorelaxing action of endogenous HO-1-derived CO. Noteworthy, no 
Figure 1 Chemical structure of 
CORM-2. Adapated from Motterlini, 
R. et al. (151). 
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differences in oxyhemoglobin (O2Hb) saturation resulted from CORM-2 administration, 
indicating that the compound does not induce CO poisoning (151). These results 
encouraged the idea that CO-RMs could be potentially used as pharmacological agents 
in the treatment of pathological states where HO-1/CO system plays a beneficial role. 
Since then, CO-RMs have been proven to mimic the HO-1/CO vasodilator, anti-
proliferative, anti-ischemic, anti-oxidant and anti-inflammatory bioactive properties and 
counteract diverse pathological conditions (148-150). CORM-2 vasorelaxing effect was 
already proven beneficial against hypertension in vivo (152). Furthermore, Kooli et al. 
demonstrated that the compound reproduces the HO modulation of vascular tone in the 
brain, exerting a significant sGC-dependent vasodilation action in the rat cerebral 
microvasculature (153). CORM-2 was also shown to prevent oxidative injury in rat 
cerebellar neurons treated with 3-nitropropionic acid, a toxin used to mimic oxidative 
stress-associated neurodegenerative pathologies. CORM-2 treated neurons are 
protected against ROS production and cell death induced by this toxin (154). Other 
studies report important cardioprotective effects of the CO-donor, particularly associated 
with the anti-oxidant and anti-inflammatory activities of CORM-2. On study shows 
CORM-2 prevents oxidative stress-induced response in vascular smooth muscle cells 
exposed to heme, suppressing the up-regulation of early growth response–1 (Egr-1). 
This molecule is a key regulator of cell proliferation and apoptosis suggested to act as 
an important trigger of inflammatory events involved in the progression of pathologies 
like atherosclerosis (155). CORM-2 was also observed to protect against oxidative injury 
induced by H2O2 in endothelial cells (156). Moreover, Importantly, CORM-2 rescues HO-
1 deficient mice from vascular arterial thrombosis during murine aortic 
allotransplantation, preventing platelet aggregation and thrombi formation in the graft, 
reinforcing the capacity of the compound to mimic the HO-1-derived CO action (157). 
CORM-2 has also been shown to exert beneficial effects on renal pathophysiology. The 
compound significantly attenuates vasoconstriction of renal afferent arterioles, following 
NO synthase suppression, and thus might provide a protective mechanism of renal 
microcirculation during stress conditions where NO system is compromised, for instance 
during endothelial dysfunction (158). Furthermore, CORM-2 treatment decreases the 
levels of plasma creatinine and restricts renal injury in a mouse model of ischemia-
induced acute renal failure (159). Noteworthy, several recent in vitro and in vivo studies 
have proved important anti-inflammatory actions of CORM-2. Treatment with CORM-2 
decreases the inflammatory response in lipopolysaccharide (LPS)-activated murine 
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macrophages, markedly reducing the production of TNF-α, IL-1β and IFN-β and 
inhibiting iNOS and NO production in these cells (160-163). The reported anti-
inflammatory effects of CORM-2 also include marked reduction of ROS formation in 
activated macrophages and neutrophils (164). Additionally, CORM-2 treatment prevents 
peroxynitrite-induced apoptosis (165). These findings are consistent with the known CO 
protective action against nitrosative and oxidative stress. Studies in human neutrophils 
and guinea pig mast cells also suggest that CORM-2 could be used in the treatment of 
allergic disease since the compound significantly attenuates the immunological release 
of histamine and the expression of CD203c, an activation marker of these cells (166). 
Importantly, the anti-inflammatory action of CORM-2 is extended to microglia, where the 
compound mimics the protective action of HO-1, induced by astrocytes as a response 
against brain inflammation. It was shown in rat microglia that the CO-donor attenuates 
the IFN-γ-elicited neuroinflammatory response, reducing nitrite formation (167). 
Likewise, CORM-2 prevents the inflammatory response induced by cytokines in human 
intestinal epithelial cells, down-regulating genes involved in intestinal inflammation and 
cancer progression, namely iNOS, IL-6, IL-8 and matrix metalloproteinase-7 (MMP-7) 
(168). Moreover, CORM-2 was shown to attenuate the pro-inflammatory response in 
LPS-stimulated human umbilical vein endothelial cells, reducing polymorphonuclear 
(PMN) leukocyte adhesion, ROS and NO production, and ICAM-1 and iNOS expression 
in these cells (169). Is of significant relevance that the anti-inflammatory properties of 
CORM-2 molecule have been confirmed in vivo using diverse models of inflammation-
associated pathologies. In a mouse model of thermal injury, CORM-2 administered 
intravenously (i.v.) clearly inhibited the inflammatory response in the liver. Hepatocyte 
injury, accumulation and adhesion of PMN leukocytes to the ECs of liver sinusoids were 
significantly diminished in CORM-2 treated mice. The anti-inflammatory effect was 
mediated by a significant decrease of TNF-α and IL-1β levels and down-regulation of 
iNOS and EC expression of VCAM-1 and ICAM-1 adhesion molecules (170, 171). A 
similar anti-inflammatory effect of the CO donor has been verified in the lung, intestine 
and renal tissue of models of thermal or ischemia injury (172-175). Notably, CORM-2 
was also shown to counteract in vivo the overwhelming systemic inflammatory response 
that occurs during sepsis (169). In fact, mice receiving CORM-2 treatment were clearly 
protected from lethal sepsis, exhibiting improved survival rates (160). Recently, CORM-2 
was also confirmed to prevent inflammation and cartilage degradation in chondrocytes 
isolated from osteoarthritis patients, highlighting CORM-2 as a potential new drug 
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candidate against osteoarthritis pathogenesis (176, 177). CORM-2 anti-inflammatory 
beneficial effects carry on to skin protection. The topic application of skin lotion 
containing CORM-2 protects mice against the immunosuppressive effects of solar-
simulated UV radiation and acts as an important anti-photocarcinogenic agent (178, 
179). Besides the remarkable findings regarding CORM-2 action on mammalians, a 
recent study also extends CORM-2 activity against pathogenic microorganisms. In fact, 
this CO donor acts as a strong anti-microbial drug against the pathogenic bacteria 
Escherichia coli and Staphylococcus aureus. These authors suggest CO-RMs as a novel 
class of anti-microbial molecules, which could be in the future used as new therapeutic 
agents to combat antibiotic-resistant pathogens (180).  
Although the beneficial effects of CO-RMs, and CORM-2 in particular, have been 
broadly confirmed, there are aspects that should be taken into consideration regarding a 
future pharmacological application of these compounds. In the case of CORM-2, there 
are studies reporting undesirable effects of the molecule, namely the activation of non-
selective cation channels independently of CO release, and alterations of axonal 
conduction in spinal cord tissue (181, 182). Importantly, the molecule is insoluble in 
water and, similarly to other CO-RMs, its specific targets are poorly known. Therefore, 
considerable interest has been put on improving and designing new CO-RMs to 
overcome these drawbacks and enhance therapeutic applicability. CORM-3, 
tricarbonylchloro(glycinato)ruthenium II (Ru[CO]3Cl(glycinate)) is a good example of a 
new and promising CO-RM, which already bears the advantage of water solubility due to 
its glycine group. Similarly to CORM-2, CORM-3 beneficial vasodilatory, anti-ischemic, 
anti-inflammatory and anti-microbial effects have been reported (148, 150, 180). 
Importantly, a new improved version of CORM-2 has also been synthesized, where 
solubility in water has been achieved through the coordination of an amino acid group, 
likewise to CORM-3. Bearing in mind the remarkable biological effects of CORM-2 we 
can envisage the high potentialities of this new CORM-2 improved compound, however, 
its biological properties have only now started to be investigated. Much work still needs 
to be conducted in order to unveil the mechanisms behind CO-RMs beneficial action. 
While the typical CO targets such as heme-containing sGC appear as important 
mediators, emerging evidences using CO-RMs more controlled delivery of CO, support 
an interaction of the gas with metal centres, specially transition metal moieties, of heme- 
or other metal-dependent proteins (183). CO-RMs research also adds further support 
regarding the downstream regulation of MAPKs signalling and transcription factors such 
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as NF-κB as crucial intervenient on the CO pleiotropic effects (184). Albeit these 
findings, the CO cellular targets remain largely unknown, and is reasonable to admit 
several hypothesis for the CO-effector mechanisms, if one takes into account the wide 
bioactivities of the molecule. Also, pharmakocinetic studies and data on CO-RMs tissue 
distribution and elimination are still expected. Despite that, research on these molecules 
has notably expanded in the past years, becoming clear that CO-RMs offer an attracting 
opportunity to exploit CO beneficial effects for therapeutic use. Indeed, the exciting 
results on CO-RMs biology, namely with CORM-2, anticipate these molecules as a new 
generation of pharmaceuticals against vascular and inflammatory diseases (148, 150). 
 
 
4. Aims of the Project 
The pathogenesis of CM is very complex. Three main processes, sequestration, 
inflammation, and hemostasis dysfunction have been implicated in this pathology.  
 
This work has two main objectives: first, to study the CO protective mechanisms in ECM 
and, second, to study the bioactivity of CO releasing molecules (CORMs) in ECM.  
 
In the first aim, we want to know if the protective effect of CO could interfere with 
parasite sequestration in the brain, as well as with neuroinflammation and chemotaxis 
processes. 
 
In the second aim, we sought to address the bioactivity and therapeutic features of 
carbon monoxide releasing molecules (CO-RMs) in experimental cerebral malaria. 
These molecules may prove to be a very useful tool to explore the potential of CO as a 
therapeutic agent. 
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5. Results 
 
5.1. CO inhalation prevents parasite accumulation/sequestration in the brain and 
neuroinflammation 
Previous work demonstrated the protective effects of heme oxygenase-1 (HO-1) and 
carbon monoxide (CO) against the development of ECM in C57BL/6 infected with 
P.berghei ANKA (PbA), preventing BBB disruption and neuroinflammation (114). 
Similarly to what was shown, we verified that inhalation of CO (250 p.p.m) for 24h, from 
day 2 to day 3 after infection prevents ECM onset in all C57BL/6 infected mice.  
Cerebral malaria is a severe neurological pathology associated to P. falciparum 
infection; in which P. falciparum infected red blood cells (iRBCs) sequestration in the 
brain microvasculature represents a critical event (22). It has been long argued that 
ECM does not reproduce in many aspects human CM. Particularly controversial has 
been the existence or not the sequestration of iRBCs in the brain microvasculature of 
mice. In the P. berghei ANKA-induced ECM it has been described a marked preference 
for leukocyte sequestration (38, 39, 42, 43) rather than for iRBCs, as seen in human CM 
(22). Hence, we aimed at assessing whether there is iRBCs accumulation/sequestration 
in the brain of infected mice and if the CO protective effects could inhibit this process. 
For this, we used a recently described system of real-time imaging to detect iRBCs, 
based on the bioluminescence of transgenic luciferase-expressing parasites of the 
rodent malaria parasite P.berghei ANKA. The levels of parasite sequestration are 
assessed by the amount of bioluminescence detected by an Intensified-charge-coupled 
device (I-CCD) photon-counting video camera (44). We established infections in 
C57BL/6 (an ECM susceptible strain) and BALB/c (an ECM resistant strain) mice of PbA 
parasites that expressed luciferase in all blood stages.  
 
Before organs collection and bioluminescence acquisition mice were perfused in order to 
avoid background signal from iRBCs in circulation that were not sequestered. The lung, 
spleen and fat tissue showed the highest bioluminescence signal in the PbA-infected 
C57BL/6 exposed to air and developing ECM (P < 0.05, comparing brain to the other 
organs; Fig. 1a,c) as well as in PbA-infected C57BL/6 mice treated with CO and PbA-
infected BALB/c mice (data not shown), whilst the brain displayed the lowest.  
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Figure 1 CO inhalation prevents P. berghei ANKA (PbA) accumulation in the brain. Visualization and 
quantification of bioluminescence in ex vivo organs of mice infected with a PbA transgenic parasites that 
express luciferase in all blood stages. Bioluminescence detected in (a) organs (15 sec exposure) and (b) 
brain (300 sec exposure) of PbA-infected C57BL/6 mice exposed to air (I) (d6 p.i.) or to CO inhalation (I + 
CO) (d6-10 p.i.) and in PbA-infected BALB/c mice (I) (d7 p.i.). Image data are representative of the 
bioluminescence profile in each group of mice. Color scale indicates the image maximum and minimum 
values of average radiance. Bioluminescence quantification in the (c) organs and (d) brain at the exposures 
referred above. B – brain, F – fat tissue, K – kidney, L – lungs, LV – liver, S – spleen.C57BL/6: I (n = 5), I + 
CO (n = 7); BALB/c: I (n = 3). Error bars represent standard deviation. 
 
This result indicates that sequestration/accumulation of iRBCs occurs mainly in the lung, 
spleen and fat; however it also occurs in the brain, though at a lower extent compared to 
the other organs. Hence, to increase the signal output, the brain bioluminescence was 
recorded separately for a longer exposition time (300 sec) than the other organs (15 
sec). We observed clear reduction in parasite accumulation/sequestration both in the 
brains of infected C57BL/6 mice treated with CO and infected BALB/c mice by 64.8 ± 
20.3% and 81.2 ± 12.8%, respectively, which did not develop ECM, at days (d) 6-10 
post-infection (p.i.), compared with the infected C57BL/6 air-exposed controls when 
ECM symptoms developed at d6 p.i. (P < 0.05 for C57BL/6 + CO and P < 0.01 for 
BALB/c; Fig. 1b,d).  
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It is known that sequestration of iRBCs in the microvasculature of organs and tissues in 
human CM is carried out primarily by mature forms of the parasite, namely by schizonts 
(22). According to this we repeated the previous experiment using a P.berghei ANKA 
parasite that only expresses luciferase at the schizont stage (44). In this manner we 
would be able to further corroborate our results by avoiding the bioluminescence from 
earlier forms of the parasite, as well as improving the resolution by increasing the 
bioluminescence signal/background ratio.  
 
The lung, spleen and fat tissue remained the organs with highest parasite 
accumulation/sequestration whereas the brain displayed the lowest levels of parasites 
accumulated and/or sequestered, similarly to what has been observed before (P < 0.05, 
brain compared with the other organs; Fig. 2a,c). The brains from infected C57BL/6 CO-
treated mice and BALB/c mice showed a significant bioluminescence decrease, 88.1 ± 
7.8 % and 91.8 ± 4.9 %, respectively, at d6-12 p.i., as compared with the air-exposed 
controls at d5-6 p.i., when ECM signs developed in these mice (P < 0.01; Fig. 2b,d). 
This data confirms the results obtained in the previous experiment. However, using the 
parasite that expresses luciferase in the schizont stage, we can observe an 
enhancement in the bioluminescent signal which emphasizes the differences in brain 
iRBCs accumulation between mice groups. Therefore, this parasite seems more 
appropriate to detect variations in the accumulation/sequestration of parasites in the 
brain. 
 
The accumulation/sequestration of P. berghei ANKA was further confirmed by 
quantitative RT-PCR (qRT-PCR) of mRNA expression of P.berghei 18S rRNA in the 
brains of the same mice from the experiment represented in Figure 1.  
Parasite accumulation quantified by mRNA expression is clearly consistent with 
bioluminescence results, showing a reduction in the infected C57BL/6 CO-treated mice 
and BALB/c mice by 64.4 ± 26.6 % and 84.5 ± 2.8 %, respectively, versus the air-treated 
controls that developed ECM (P < 0.05 for C57BL/6 + CO and P < 0.01 for BALB/c; Fig. 
3a). 
 
Moreover, to confirm the ECM and ECM-protected phenotypes we analysed the brain 
neuroinflammatory status by assessing the mRNA expression of CD3 and CD8, in order 
to assess the recruitment of CD8+ T cells into the brain microvasculature, a key 
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pathological feature of ECM (72) shown to be inhibited upon CO treatment 
(114).
 
 
Additionally, the expression of granzyme B was also determined to assess the activation 
of CD8+ T cells. All these markers were significantly down-regulated in the infected 
C57BL/6 mice exposed to CO inhalation and BALB/c mice as compared to the infected 
C57BL/6 air-exposed controls, which developed all neurological signs of disease. We 
observed a reduction in CD3 expression by 33.5 ± 9.6 % and 56.3 ± 6.4 %, in CD8 
expression by 74.5 ± 3,2 % and 83.2 ± 5.6 % and in granzyme B expression by 72.2 ± 
12.9 % and 72.0 ± 5.8 % in C57BL/6 CO-exposed mice and BALB/c mice, respectively, 
as compared to air-exposed controls (Cd3, Cd8, Gzmb, P < 0.01 Fig. 3b-d). 
Figure 2 CO inhalation prevents accumulation of P. berghei ANKA schizonts in the brain. Visualization 
and quantification of bioluminescence in ex vivo organs of mice infected with a PbA transgenic parasites 
that express luciferase only in schizonts. Bioluminescence detected in (a) organs (20 sec exposure) and 
(b) brain (300 sec exposure) of PbA-infected C57BL/6 mice exposed to air (I) (d5-6 p.i.) or to CO 
inhalation (I + CO) (d6-12 p.i.) and in PbA-infected BALB/c mice (I) (d6 p.i.). Image data are 
representative of the bioluminescence profile in each group of mice. Color scale indicates the image 
maximum and minimum values of average radiance. Bioluminescence quantification in the (c) organs 
and (d) brain at the exposures referred before. B – brain, F – fat tissue, K – kidney, L – lungs, LV – liver, 
S – spleen.C57BL/6: I (n = 5), I + CO (n = 7); BALB/c: I (n = 3). Error bars represent standard deviation. 
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Figure 3 CO inhalation inhibits parasite accumulation/sequestration and neuroinflammation. (a-f) 
Assessement, by qRT-PCR, of brain mRNA expression of PbA 18S rRNA (r18S), CD3 (Cd3), Granzyme 
B (Gzmb), CD8 (Cd8) IP-10 (Ip-10) and CXCR3 (Cxcr3) genes in C57BL/6 mice non-infected (NI), PbA-
infected and exposed to air (I) (d6 p.i.), CO inhalation (I + CO) (d6-10 p.i), and in PbA-infected BALB/c 
mice (I) (d7 p.i.). Expression is normalized to hprt expression and is shown as percentage of expression 
in control C57BL/6 infected mice exposed to air. C57BL/6: NI (n = 2), I (n = 5), I + CO (n = 3); BALB/c: I 
(n = 4) Error bars represent standard deviation. 
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In addition, the expression of the chemokine IP-10 and its receptor CXCR3 was also 
investigated, since these molecules have been recently implied in ECM by playing a role 
in CD8+ T lymphocytes migration to the brain microvasculature (84-86). IP-10 is clearly 
up-regulated in the brains of C57BL/6 air-exposed controls that developed ECM, at d6 
p.i., and comparatively reduced by 70.4 ± 29.5 % in the C57BL/6 CO-treated mice, at 
d6-10p.i.(P < 0.01), while in BALB/c mice, at d7 p.i., IP-10 showed no significant 
differences (Fig. 3e). On the other hand, CXCR3 expression in the brain showed no 
differences between mice groups (P > 0.05; Fig. 3f).  
 
5.2. CORM-2 protects against ECM development 
We tested if the protection conferred by CO inhalation could be mimicked by the 
administration of CO-RMs. These compounds would bring the advantage of a more 
specific and controlled delivery of CO to cells and thereby overcome the toxicity of CO 
inhalation due to COHb production (150). 
 
For this purpose, we tested the tricarbonyldichlororuthenium (II) dimer ([Ru(CO)3Cl2]2) 
i.e. CORM-2 (dissolved in DMSO 10% in PBS; vehicle) which has been proven to act 
beneficially in several mouse models of pathology by suppressing inflammation (169, 
170, 175). C57BL/5 mice infected with P.berghei ANKA were administrated 
intravenously (i.v.) with CORM-2 at the indicated times after infection.  
 
A concentration of 10 mg/kg of body weight of CORM-2, given at day 3 p.i. or at d3 and 
d4 p.i., proved to be ineffective, with all the infected C57BL/6 mice developing ECM (Fig. 
4a,b). However, increasing the concentration of CORM-2 to 20 mg/kg and administration 
from d2 until d4 p.i., twice a day, prevented ECM symptoms in all C57BL/6 infected 
mice, while all the infected C57BL/6 controls administrated with the DMSO vehicle died 
at d6-7 p.i. from ECM (Fig. 4c). The CORM-2-treated mice die after 3 weeks of infection 
with hyperparasitemia However, contrary to what occurred with CO inhalation, we 
observed an arrest in parasitemia between d5 to 7 p.i in CORM-2 treated mice. 
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Parasitemia was significantly decreased in the CORM-2 treated mice at day 6 p.i., the 
day of ECM onset in DMSO controls (P < 0.05). After day 8 p.i. the levels of parasitemia 
start to increase rapidly, reaching a typical plateau around day 16 p.i. (Fig. 4d).  
 
Thereafter, different schedules, concentrations and routes of administration 
(intraperitoneally, i.p., or i.v.) of CORM-2 were tested in P.berghei-ANKA infected 
C57BL/6 mice. We observed that CORM-2 (20mg/kg) administration at d2 and d3 p.i, 
twice a day was sufficient to prevent the development of ECM in 100% of the mice, while 
 
Figure 4 CORM-2 mimics CO protective effect and abrogates ECM development. (a, b) Survival and 
mean parasitemia of PbA-infected C57BL/6 mice (I) receiving no treatment or administered i.v. with 
CORM-2 (I + CORM-2) (10mg/kg of body weight) once a day (1x) at d3 p.i. or at d3 and d4 p.i. (c, d) 
Survival and mean parasitemia of infected mice administered i.v. either with CORM-2 (20mg/kg) (I + 
CORM-2) or DMSO vehicle (I + DMSO) twice a day (2x) at d2 and d3 p.i. I (n = 5); I + DMSO (n = 5); I + 
CORM-2 (n = 4-8). Error bars represent standard deviation. 
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the administration of CORM-2 one time per day at the same days was not. Though, if 
CORM-2 was given once a day but from d2-4 p.i., all mice were protected (Fig. 5a,b). 
Additionally, i.p. route of administration was tested since it has the advantage of being 
less invasive than i.v. In parallel we also wanted to know if CORM-2 given i.v. at a lower 
concentration, 10 mg/kg, was protective when administered at d2 and d3 p.i once a day. 
Nevertheless, we observed that neither CORM-2 given i.p. nor CORM-2 at a 10mg/kg 
concentration prevented ECM (Fig. 5c,d) 
. 
 
Again, we observed an arrest in parasitemia between d5 to d7 p.i in CORM-2 treated 
mice that did not develop ECM (Fig. 5b). Parasitemia in these mice was significantly 
 
Figure 5 CORM-2 abrogates ECM development. P.berghei-ANKA infected C57BL/6 mice. PbA-infected 
C57BL/6 mice were treated with CORM-2 (I + CORM-2) or DMSO vehicle (I + DMSO) (a, b) Effect on 
survival and mean parasitema of several schedules of administration of CORM-2 (20mg/kg): twice a day 
(2x) from d2-4 p.i. or from d2-3 p.i.; once a day (1x) from d2-4p.i. or from d2-3p.i. (c, d) Effect on survival 
and mean parasitemia of i.p. administration of CORM-2 (20 mg/kg) (2x) from d2-3 p.i. or i.v. 
administration of CORM-2 (10mg/kg) (1x) from d2-3 p.i. I + DMSO (n = 4-7); I + CORM-2 (n = 3-6). Error 
bars represent standard deviation. 
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reduced at d5 p.i. and d6 p.i., compared with DMSO controls that started to develop 
ECM (P < 0.05). No differences appear to occur on parasitemia during the non-
protective schedules of CORM-2 administration. Whether this small but significant arrest 
in parasitemia for 3 days is important for the protective effect of CORM-2 is not known. 
For the following experiments CORM-2 was administered i.v. twice a day at d2 and d3 
p.i. 
 
5.3. CORM-2 protective effects is dependent on CO release but does not involve 
COHb formation 
Furthermore, to confirm that CORM-2 protection was due to CO release and not due to 
other constituents of the compound, like the ruthenium centre of the molecule, we tested 
the effect of the negative control compound, generically named as ALF466, which is 
similar to CORM-2 however does not contain CO molecules.  
 
 
Treatment with ALF 466 revealed ineffective against ECM in all mice whereas CORM-2 
prevented all infected C57BL/6 mice from developing the pathology. Again, we observed 
the parasitemia arrest from d4 to d8 p.i. in the CORM-2 -protected mice (Fig. 6a,b) but 
not in the ALF466 treated mice. Because ALF 466 does not contain any CO molecule, 
 
Figure 6 CORM-2 protective effects are due to CO donation. (a, b) Effect on survival and mean 
parasitemia of CORM-2 (20mg/kg) (I + CORM-2), ALF 466 (at equimolar concentration to CORM-2) (I + 
ALF466), or DMSO vehicle (I + DMSO) i.v. administration (2x) from d2-d3 p.i. in PbA-infected C57BL/6 
mice. I + DMSO (n = 5); I + CORM-2 (n = 7); I + ALF 466 (n = 6). Error bars represent standard 
deviation. 
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this results demonstrates that CO is the responsible for CORM-2 protection against 
ECM.  
 
Importantly, we also wanted to assess if CORM-2 treatment would induce the formation 
of carboxyhemoglobin, as observed for CO inhalation, or, on the contrary, is able to 
overcome the toxicity effect of CO inhalation. 
 
 
 
Figure 7 CORM-2 treatment does not induce COHb production. COHb and O2Hb measurement in whole 
blood of non-infected (NI) and PbA-infected C57BL/6 mice treated with DMSO vehicle (I + DMSO), CO (I 
+ CO) or CORM-2 (I + CORM-2) (a) 15 min. after first CORM-2 administration, at d2 p.i., (b) 3h after first 
CORM-2 administration, at d 2 p.i. (c) and immediately after CO treatment / last CORM-2 administration, 
at d3 p.i. (d, e) O2Hb, COHb and MetHb measurement in whole blood of non-infected, PbA-infected 
C57BL/6 mice treated with DMSO vehicle at the time of ECM development (at d6 p.i.), treated with CO 
(at d6-7 p.i.) or treated with CORM-2  (at d6-7 p.i.). NI (n= 4-9); I + DMSO (n = 3-4); I + CO (n = 4); I + 
CORM-2 (n = 5-6). Error bars represent standard deviation. 
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In fact, the levels of oxyhemoglobin (O2Hb) and carboxyhemoglobin (COHb) revealed no 
significant differences in the whole blood of C57BL/6 infected mice treated with CORM-2 
versus DMSO-treated controls, either 15 minutes or 3 hours after the first CORM-2 
administration (P > 0.05; Fig. 7a,b). Moreover, we compared the levels of COHb at d3 
p.i., immediately after CO treatment or after last CORM-2 administration. We observed 
that CO inhalation strongly induces COHb formation (P < 0.01) while CORM-2 does not 
induce COHb formation when compared with non-infected or infected DMSO-treated 
mice (Fig. 7c). Finally, at d6 p.i., methemoglobin (MetHb) is found significantly increased 
in the DMSO-treated controls showing signs of ECM whereas CO-treated and CORM-2-
treated mice exhibit significant lower levels of MetHb (P < 0.01 and P < 0.05, 
respectively), similar to the non-infected mice (Fig. 7e).  
 
5.4. CORM-2 prevents parasite accumulation/sequestration in the brain and 
neuroinflammation - CORM-2 mimics CO inhalation  
Of special importance is the quantification of parasite accumulation/sequestration in the 
brain during the treatment with CORM-2. We assessed this through the same 
bioluminescence system used previously, with the P. berghei ANKA that expresses 
luciferase only at the schizont stage.  
 
We obtained a significant reduction in brain bioluminescence by 76.3 ± 29.3 and by 97.2 
± 1.8 in the C57BL/6 infected mice treated with CORM-2 (P < 0.05) and in the BALB/c 
infected mice (P < 0.01), respectively, compared with C57BL/6 infected mice that 
received the control molecule ALF466, and that developed ECM (Fig. 8). This shows 
that CORM-2 mimics the effect of CO inhalation on parasite accumulation/sequestration 
in the brain and reinforces the importance of iRBCs accumulation/sequestration in the 
development of ECM in C57BL/6 P.berghei ANKA-infected mice. By qRT-PCR we 
obtained consistent results with the data obtained by bioluminescence acquisition. 
Indeed, we observed a reduction by 61.1 ± 17.4 % in parasite accumulation in the brains 
of mice that received CORM-2 treatment versus the DMSO treated controls that 
developed ECM (P < 0.05; Fig. 9a). 
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Since blood-brain barrier (BBB) disruption and neuroinflammation are hallmarks of ECM, 
the occurrence of these two processes were assessed in the context of CORM-2 
treatment to better characterize de protected phenotype. CORM-2 administration 
prevented BBB disruption in C57BL/6 PbA infected mice, as showed by the levels of 
Evans blue accumulation in the brain parenchyma, not significantly different from the 
non-infected controls. In contrast, C57BL/6 infected controls treated with DMSO vehicle 
and developing ECM showed a significant increase in BBB permeability. A 6 fold 
increase in Evans blue accumulation in the brain parenchyma was observed in these 
mice, when compared with non-infected mice, indicating BBB disruption (P < 0.05; Fig. 
10).  
 
We also assessed the brain mRNA expression of various genes associated to 
inflammation to confirm that CORM-2 protective effect, similarly to CO, was related with 
the modulation of inflammatory ECM-associated events. We confirmed if CORM-2 
treatment also inhibited the recruitment of CD8+ T cells and the brain expression of IFN-
γ and the adhesion molecule ICAM-1, known to play a critical role in the pathology (69, 
92). IFN-γ and ICAM-1 have been already described to be down-regulated in the brains 
Figure 8 CORM-2 treatment suppresses the accumulation P. berghei ANKA schizonts the brain. 
Visualization and quantification of bioluminescence in ex vivo brains of mice infected with PbA parasites 
that express luciferase only in the schizonts. (a) Detection of bioluminescence (300 sec exposure) and 
(b) quantification in the brains of PbA-infected C57BL/6 mice treated with ALF466 (I + ALF466) (d6 p.i.) 
or with CORM-2 (I+ CORM-2) (d6-12 p.i.) and in PbA-infected BALB/c mice (d7 p.i.). Image data are 
representative of the bioluminescence profile in each group of mice. Color scale indicates the image 
maximum and minimum values of average radiance. C57BL/6: I + ALF466 (n = 3), I + CORM-2 (n = 5); 
BALB/c: I (n = 4). Error bars represent standard deviation. 
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of mice protected by CO inhalation (112). In C57BL/6 infected mice, CORM-2 reduced 
the brain CD3 and CD8 mRNA by 54.0 ± 16.7 % and 64.1 ± 17.0 %, respectively, in 
comparison with DMSO-administered controls suffering from ECM (P < 0.05, Cd3 and 
Cd8 expression; Fig. 9b,c). 
  
 
 
Figure 9 CORM-2 treatment prevents parasite accumulation/sequestration and neuroinflammation. (a-e) 
Brain mRNA expression assessed by qRT-PCR of PbA 18S rRNA (r18S), CD3 (Cd3), CD8 (Cd8) IFN-γ 
(Ifng) and ICAM1 (Icam1) genes, in C57BL/6 non-infected (NI) and PbA-infected (I) mice treated with 
DMSO vehicle or CORM-2. Expression is normalized to that of Hprt and is shown as percentage of 
expression in control C57BL/6 infected mice exposed to air. NI (n = 2-3); I / DMSO (n = 3); I / CORM-2 (n 
= 3). Error bars represent standard deviation. 
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IFN-γ and ICAM-1 were also significantly down-regulated in the CORM-2-treated mice, 
by 72.1 ± 16.4 % and 45.2 ± 4.8 %, respectively, versus DMSO-treated controls (P < 
0.01 Ifng and Icam1 expression; Fig. 9d,e) 
 
 
 
5.5. CORM-2 changes the profile of intra-erythrocytic stages of P.berghei ANKA 
CORM-2 treatment leads to a delay in the progression of parasitemia, between d5 to d7 
p.i. To attain some evidence about whether this effect resulted from impairment in the 
parasite intra-erythrocytic development, we looked at the percentage of rings and more 
mature parasite forms (trophozoites and schizonts), between C57BL/6 mice infected with 
P.berghei ANKA GFP-expressing parasites (PbA-GFP), that have received either 
CORM-2 or DMSO vehicle. We distinguished the developmental blood stages of the 
parasite based on the parasite GFP-fluorescence and DNA content, by staining with 
Hoechst DNA-specific fluorescent dye, as previously reported (185).  
 
In the peripheral blood of CORM-2 treated mice, at day 6 p.i., we observed a significant 
reduction (19.8 ± 6 %; P < 0.01) in the percentage of ring forms, parasites at an early 
stage of infection. But in contrast, we observed a significant increase in the percentage 
of circulating trophozoites and schizonts, mature forms of the parasite, by 15.9 ± 5.2 % 
in the CORM-2 treated mice, as compared with controls receiving DMSO and in ECM (P 
< 0.01). Additionally, in CORM-2 treated mice we observed a significant 1.5 ± 0.6 % 
higher gametocyte fraction of parasites (P < 0.01; Fig. 11). 
 
Figure 10 CORM-2 prevents BBB disruption in P.berghei ANKA infected mice. BBB disruption was 
determined by Evans Blue (EB) quantification in C57BL/6 non-infected (NI) or PbA-infected (I) mice 
either treated with CORM-2 or DMSO vehicle. NI (n = 3); I / DMSO (n = 3); I / CORM-2 (n = 4). Error 
bars represent standard deviation.expression  
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5.6. CORM-2 does not alter reticulocytosis significantly 
Some Plasmodium species like P. berghei and P. yoelli 17XL show a preference for 
invading reticulocytes (young erythrocytes) over mature erythrocytes (186, 187). In fact, 
it has been established a correlation between reduction in P. yoelli 17XL parasite load in 
circulation and IFN-γ-induced suppression of erythropoiesis and reticulocytosis (187). 
Bearing this in mind, we sought to investigate whether CORM-2 treatment could be 
inhibiting erythropoiesis, thus reducing reticulocyte levels and by this way retarding 
parasitemia progression between day 5 and 8 p.i.  
At day 3 p.i., reticulocytemia (the percentage of reticulocytes in the total population of 
red blood cells), assessed by flow cytometry, showed no differences between C57BL/6 
mice non-infected or infected with PbA and receiving DMSO vehicle.~ 
Figure 11 Treatment with CORM-2 reduces the proportion of P. berghei ANKA schizonts in peripheral 
blood. (a) Dot plot (upper row) and histogram (lower row) showing the distribution of parasite blood 
stages by flow cytometry. Graphics show Hoechst (DNA stain) and GFP fluorescence intensity of 
peripheral RBCs of C57BL/6 mice infected with PbA-GFP, treated with DMSO vehicle (I + DMSO) or 
CORM-2 (I + CORM-2). Data are representative of each experimental group. (b) Percentage of PbA 
blood stages in the infected C57BL/6 mice treated with CORM-2 or DMSO vehicle. I + DMSO (n = 5); I + 
CORM-2 (n = 5) Error bars represent standard deviation. 
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However, a slight but significant increase in the CORM-2 treated mice was observed, 
when compared with the DMSO-treated mice (P < 0.05). At day 6 p.i. all infected mice 
 
 
Figure 12 CORM-2 treatment does not seem to induce significant alterations in reticulocytosis. 
Reticulocytemia was assessed by flow cytometry in C57BL/6 non-infected mice (NI) or in C57BL/6 PbA 
GFP-infected mice (I) treated with DMSO vehicle or CORM-2. Blood cells were stained for CD45 and 
CD71, and reticulocytes were gated in the CD45-CD71+ cell population (a) Dot plots as measured by 
flow cytometry, showing CD71 expression and GFP fluorescence intensity. Numbers in quadrants 
indicate adjacent percent cells in each. Data is representative of each group of mice. (b) 
Reticulocytemia, reticulocyte index (c) and absolute number of parasitized reticulocytes per volume of 
blood, at d3 p.i and d6 p.i. NI (n = 2-3); I + DMSO (n = 3); I + CORM-2 (n = 5). Error bars represent 
standard deviation. 
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showed a strong reduction in reticulocytosis, when compared with the non-infected mice. 
This is in accordance with previous observations reporting a decrease in circulating 
reticulocytes upon a P. berghei infection, due to the tropism of the parasite for 
reticulocytes (186), but should also result from the inhibiton of erythropoiesis that 
typically occurs during a malaria infection (136). At this day, reticulocytemia also shows 
a small increase in the CORM-2 protected when compared with DMSO-treated control 
mice, that were showing signs of ECM (P < 0.05; Fig. 12a,b). In parallel, the number of 
infected reticulocytes per volume of blood was also determined by flow cytometry. In 
these results we noticed a high variability within groups, possibly caused by errors 
associated with cell counting method (beads). At d3 p.i. and d6 p.i CORM-2-treated mice 
seem to show increased numbers of parasitized reticulocytes when compared with 
control mice that received DMSO vehicle, although this was not significant (Fig. 12c). 
Importantly, we calculated the reticulocyte index, which has into account the hematocrit 
(the proportion of blood volume occupied by RBCs). This is a more accurate measure of 
reticulocytosis, particularly in situations where RBC number is decreased, such as 
hemolysis induced by a malaria infection. The reticulocyte index determined for d6 p.i. 
revealed no differences between mice receiving CORM-2 or DMSO vehicle (Fig.12b) 
suggesting that CORM-2 doe not induce significant alterations in reticulocytosis. 
 
5.7. CORM-2 treated mice show a reduced hematocrit and platelet volume 
To further understand the effect of CORM-2 treatment in the peripheral blood, we looked 
to further hematological parameters, such as hematocrit, total number of RBCs per 
volume, hemoglobin concentration and platelet number. All these parameters were 
assessed for the DMSO-administered controls at day 6 p.i., the day of ECM onset in 
these mice.  
 
C57BL/6 PbA-infected mice protected by CORM-2 treatment evidence a significant 
reduction of 14.3 ± 2.2 % in hematocrit, when compared with DMSO-treated control mice 
(P < 0.01) (Fig. 13a). 
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In straight agreement with this, RBC number and hemoglobin concentration were 
similarly decreased in the blood of CORM-2 treated mice, respectively, by 34.0 ± 4.9 % 
and 35.3 ± 4.7 % compared with DMSO controls (P < 0.01), while between non-infected 
and DMSO treated mice no differences appeared to occur (Fig. 13b,c).  
 
Additionally, we assessed whether CORM-2 could be affecting platelets, which have 
been associated with human and rodent CM (95, 97). At day 6 p.i., the day of ECM 
onset in DMSO-treated controls, platelet counts appear decreased in all infected mice, 
when compared with non-infected ones, which was expected in Plasmodium infections. 
During malaria infection thrombocytopenia (the loss of platelets in circulation) in human 
and experimental malaria has been reported (95). However, the number of platelets 
showed no significant differences between CORM-2-treated mice and DMSO controls 
 
Figure 13 CORM-2 treated mice show a reduction in hematocrit. (a) Hematocrit, (b) number of RBCs 
per volume (c) and hemoglobin concentration were assessed in the peripheral blood of C57BL/6 mice 
non-infected (NI) or C57BL/6 PbA-infected mice (I) treated with CORM-2 (d6-7 p.i.) or DMSO vehicle (d6 
p.i.). NI (n = 2); I + DMSO (n = 5); I + CORM-2 (n = 5). Error bars represent standard deviation. 
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(Fig. 14a). Inversely, all infected mice seemed to show a larger platelet volume relatively 
to non-infected mice, but platelets from CORM-2 treated group have significant smaller 
average volumes when compared with DMSO-treated mice (P < 0.01; Fig 14b).  
 
 
 
5.8. CORM-2 treatment increases the number of phagocytic cells in circulation 
Furthermore, to evaluate the CORM-2 effect in the immune response, leukocyte counts 
were assessed in the peripheral blood of DMSO-treated controls with ECM, at day 6 p.i., 
and CORM-2 treated groups at day 6-7 p.i. It was observed a significant increase in both 
circulating monocytes and neutrophils upon CORM-2 treatment, comparatively with the 
DMSO controls (P < 0.05; Fig. 15a,b). Lymphocyte numbers were not significantly 
altered between these groups (Fig. 15c). 
 
 
Figure 14 CORM-2 reduces average volume of platelets. (a) Platelet number per volume of blood (b) 
and average volume of platelets in the peripheral blood of C57BL/6 mice non-infected (NI) or infected 
with PbA (I) and treated with CORM-2 (d6-7p.i.) or DMSO vehicle (d6 p.i.). Note scale break. (n = 2); I + 
DMSO (n = 5); I + CORM-2 (n = 5). Error bars represent standard deviation. 
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5.9. Spleens from CORM-2 treated mice have increased weights 
Spleen weights were also measured in C57BL/6 non-infected or PbA-infected C57BL/6 
mice, treated with CORM-2 or DMSO vehicle. As expected, the spleens of infected mice 
are larger than non-infected (P < 0.01). Furthermore, we observed a significant increase 
in spleen weight in CORM-2-treated mice (P < 0.01) compared to DMSO controls, 
possibly related to and increased removal of RBCs (Fig. 16). 
 
 
 
Figure 15 CORM-2 treatment increases the number of monocytes and neutrophils in peripheral blood of 
PbA-infected mice. The number of circulating (a) monocytes, (b) neutrophils and (c) lymphocytes, was 
determined in C57BL/6 mice non-infected (NI) or infected with PbA (I) and treated with CORM-2 (d6-
7p.i.) or DMSO vehicle (d6 p.i.). NI (n = 2); I + DMSO (n = 5); I + CORM-2 (n = 5). Error bars represent 
standard deviation. 
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5.10. CORM-2 prevents loss of RBC deformability 
Reduced RBC deformability proved to be a strong predictor of human malaria severity 
and seems to occur principally in uninfected RBCs (35, 188). Loss of deformability is 
suggested to result from oxidative damage to membranes of RBCs by the release of 
heme products into circulation, such as hemozoin, during schizont rupture. 
Consequently, an increase of RBC rigidity may contribute to impairment of 
microcirculation and to microvasculature congestion (189, 190).  
Based on this, we hypothesized that CORM-2 treatment may reduce deformability in 
RBCs during infection. The results support our hypothesis showing that C57BL/6 PbA-
infected mice treated with CORM-2 exhibit a tendency for increased deformability, 
significantly higher for shear stress of 12 to 60 Pa, compared with DMSO-treated 
controls (P < 0.05). In fact, CORM-2 treatment seems to increase RBC deformability to 
the basal levels of non-infected control DMSO-treated, at shear stress stresses from 6-
60 Pa, although we could not statistically validate this result due to a unique mouse in 
the non-infected group. Also, CORM-2 treatment seems to elevate RBC deformability in 
the non-infected mouse, at same range of shear stresses (6-60 Pa), comparatively with 
the non-infected mouse that received DMSO vehicle (Fig. 17). 
 
 
Figure 16 CORM-2 treated mice show increased spleen weight. Spleen fresh weight in C57BL/6 mice 
non-infected (NI) or infected with PbA (I) and treated with CORM-2 (d-7p.i.) or DMSO vehicle (d6p.i.). NI 
(n = 5); I + DMSO (n = 5); I + CORM-2 (n = 5). Error bars represent standard deviation. 
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Figure 17 CORM-2 prevents loss of RBC deformability during infection. RBC deformability was 
measured in the peripheral blood f non-infected C57BL/6 mice treated with CORM-2 (NI + CORM-2) or 
DMSO (NI + DMSO) and in PbA-infected C57BL/6 mice treated with CORM-2 (I + CORM-2) or DMSO (I 
+ DMSO) at day 6 p.i. Results are indicated as mean elongation index, shown as percentage, measured 
over a range of 0.3-60 Pa of shear stress. NI (n = 1); NI + CORM-2 (n = 1); I + DMSO (n = 3); I + CORM-
2 (n = 3). Error bars represent standard deviation. 
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6. Discussion 
 
The pathogenesis of CM has been explained mainly by two processes, sequestration 
and inflammation, and more recently hemostasis dysfunction has been also implicated 
(21). Sequestration process has been considered a common feature in human and 
murine CM, although in murine CM leukocytes are the cells that predominantly 
sequester in the brain (38, 39, 42, 43) rather than iRBCs, as seen in human CM (22, 25). 
This observation has contributed to the controversy concerning the relevance of PbA-
C57BL/6 model as a CM model. Nevertheless many authors have contributed for the 
elucidation of the importance of PbA iRBCs sequestration in ECM development. Using 
the same system of real-time imaging by bioluminescence detection, some authors 
report an irrelevant accumulation of iRBCs in the brain (44) whether others correlate 
ECM onset with increased parasite sequestration in the mouse brain (45, 46).  
 
To address if the CO protective effect observed in ECM (114) could be due to a 
reduction in the parasite accumulation/sequestration in the brain of PbA-infected 
C57BL/6 mice, we used the same system of real-time imaging to detect parasite 
sequestration. We observed that the lung, spleen and fat tissue showed the highest 
bioluminescence signal, as previously reported (44), both in the PbA-infected C57BL/6 
exposed to air and developing ECM, as well as in PbA-infected C57BL/6 mice treated 
with CO and PbA-infected BALB/c mice. Comparatively, the brain was the organ with 
lower bioluminescence signal indicating a lower parasite accumulation. Nevertheless, we 
could clearly detect the presence of parasite in this organ when higher camera 
exposition times were applied (300 sec). This could explain why in a previous report (44) 
the authors could not detect significant parasite sequestration in the brain, since the 
exposition times used were far to low (10-60 sec). We observed a clear reduction in the 
parasite accumulation/sequestration in the brains of infected C57BL/6 mice treated with 
CO and infected BALB/c mice, which did not develop ECM, relatively to the PbA-infected 
C57BL/6 that developed ECM (Fig. 1). Additionally, since mature trophozoites and 
schizonts are the parasite stages that sequester during human pathology (22) we 
infected mice with a strain of PbA that only expresses luciferase in schizonts in order to 
favor the bioluminescence signal produced by sequestering parasites. The results 
obtained with this PbA strain were in strict agreement with the data obtained previously, 
indicating a significant accumulation of PbA schizonts in the brain of C57BL/6 mice 
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developing ECM, compared with CO-protected C57BL/6 mice or with BALB/c mice. In 
addition, we observed that the differences in parasite accumulation between mice 
groups were rendered more evident, most likely due to reduction in signal noise resultant 
from non-sequestering parasites (Fig. 2). This indicates that the PbA strain expressing 
luciferase only in schizonts is more appropriate to study parasite sequestration. 
Additionally, these results were further confirmed by qRT-PCR of mRNA expression of 
PbA 18S rRNA in the brains of the same mice used previously (Fig. 3a).  
 
In preceding studies (45, 46), parasite sequestration was only assessed using the PbA 
parasite that expresses luciferase in all blood stages, and therefore it is probable that the 
bioluminescence results could have been affected by the presence of non-sequestering 
parasite forms, such as ring forms and trophozoites, accumulated in brain hemorrhages 
observed in mice that developed ECM. Moreover, in the previous reports, the authors 
could not exclude the hypothesis that the decrease of iRBC in the brains of mice 
protected against ECM resulted from reduced parasite load in circulation, since these 
mice had significant lower parasitemias than control C57BL/6 PbA-infected mice that 
developed cerebral pathology (45, 46). In our study this problem does not poses 
because CO-protected mice and BALB/c mice analyzed from day 6-12 p.i. did not have 
lower parasitemias compared with control mice. In addition, it should be noted that the 
method of imaging used does not allow a clear distinction between iRBCs accumulation 
and sequestration. However, if parasite sequestration was not accounting for the 
observed results, we would not expected that infection with PbA  luciferase-expressing 
shizonts resulted in more pronounced differences in brain bioluminescence between 
mice that develop ECM and mice that are ECM-resistant, as observed.  
 
It is true that CD36 was suggested to be the major adhesion receptor mediating iRBC 
sequestration in mice and it was shown that abrogation of this molecule does not 
prevent ECM development (44). However, the authors did not assess brain 
sequestration and it is probable that other adhesion molecules, such as ICAM-1 may 
play an important role in the sequestration process. Indeed, ICAM-1-mediated 
cytoadherence of iRBCs to brain microvessels has been correlated with CM (93). 
Moreover, ICAM-1 expression is required for ECM establishment, playing a role in 
leukocyte and iRBC vascular sequestration in the murine model (94). Therefore it is 
reasonable to presume that inhibition of iRBCs sequestration in the CO-treated mice 
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arises, at least in part, from ICAM-1 down-regulation in the brain, which was shown to 
occur in mice protected by CO inhalation (114). Thereby, although brain histological 
examinations should be done in the future to complement the data presented, the 
findings obtained in the present study strongly suggest that protection by CO inhalation 
against ECM comprises the reduction of iRBC sequestration in the brain of PbA-infected 
C57BL/6 mice, and that a reduced parasite sequestration is associated with a CM-
resistant like phenotype, as verified with BALB/c mice.  
 
In summary these results, altogether, reinforce once more the importance of iRBC 
sequestration in ECM development and consequently underline the relevance of 
C57BL/5 PbA-infected mouse model to study CM pathogenesis. 
 
It has been demonstrated that CD4+ and CD8+ T cells are required for cerebral 
pathology of P. berghei ANKA-infected mice, of which CD8+ T cells play a crucial role 
(71-77). We show that recruitment of T cells and CD8+ T cells in particular, assessed by 
CD3 and CD8 expression, respectively, is reduced in the brain of C57BL/6 air-exposed 
controls and in BALB/c mice. Moreover, the cytolytic activity of CD8+ T cells in the brain, 
assessed by granzyme-B expression, is decreased in CO-treated C57BL/6 mice and in 
BALB/c mice (Fig. 3b-d). Thus, we show that CO treatment prevents the recruitment of 
activated CD8+ T cells to the brain, consistently to what was reported before (114). 
Moreover, we demonstrate that the protection conferred by CO against ECM consists of 
inhibiting essentially the presence of CD8+ T cells potentially cytotoxic to the brain 
endothelium. This was consistent with previous reports implicating perforin/granzyme B 
cytolytic pathway as a major mechanism employed by CD8+ T cells during ECM (80). 
Moreover, a survey of brain gene-expression patterns between ECM-resistant and ECM-
susceptible mouse strains identified granzyme B up-regulation to be specifically 
associated with an ECM-susceptible phenotype (191).  
 
In addition, the expression of the chemokine IP-10 and its receptor, CXCR3, was also 
assessed, since they have been shown to a play significant role in ECM by mediating 
leukocyte migration to the brain, in particular of CD8+ T cells (46, 84-86). Furthermore, 
recent studies have identified IP-10 as a biomarker associated with higher risk of CM-
associated mortality during P. falciparum infections (87, 88). The expression of IP-10 
was significant decreased in CO protected C57BL/6 mice but in BALB/c mice IP-10 
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showed no significant differences relatively to C57BL/6 air-exposed control mice that 
developed ECM (Fig. 3e). These results indicate that CO seems to have a therapeutic 
potential as a molecule with anti-chemotaxis effect in ECM. Accordingly, it has been 
suggested that inhibition of leukocyte trafficking through depletion of IP-10 could be used 
as a potential adjunctive therapy to improve treatment outcomes of CM (46). In fact, IP-
10 down-regulation in the brain could explain the reduction in CD8+ T cell recruitment to 
the brain resulting from CO treatment. On the other hand, high expression of IP-10 in 
BALB/c mice is in agreement with previous work indicating that this chemokine is up-
regulated in BALB/c mice after day 6 p.i., and consequently should not account for the 
ECM-resistant phenotype observed in this strain (86). On the other hand, CXCR3 
expression in the brain showed no differences between the groups of mice (Fig. 3f). 
These results could be explained because, as has been previously shown, CXCR3 
expression is required for early migration of activated CD8+ T cells from the spleen to the 
brain of infected mice (84, 86); and due to the redundancy of the chemokine system 
others have suggested that at later stages of disease, migration of CD8+ T cells by a 
CXCR3-independent process can be significant (84). However, given that previous 
reports demonstrated a clear induction of brain CXCR3 expression in response to PbA 
infection, further work is required to disclose why this was not observed in the present 
study. 
 
A prospective therapy by CO administration seems attractive; however treatment by CO 
inhalation has practical limitations. CO reacts promptly with hemoglobin and other 
hemoproteins before reaching the target tissue and thus can potentially induce clinical 
toxicity. To overcome these problems, we tested if the protection conferred by CO 
inhalation against ECM could be mimicked by the administration of CO-releasing 
molecules, because these molecules are thought to act as more specific CO-donors to 
cells and tissues and have been shown to mimic the anti-oxidant and anti-inflammatory 
properties of CO in a variety of pathophysiological conditions. Due to this, CO-RMs have 
been defended as potentially good candidates for CO-based pharmaceuticals (148, 
150).  
 
Strikingly, we observed that administering CORM-2 at a concentration of 20 mg/kg of 
body weight, given i.v. two times per day, from day 2-3p.i. was sufficient to have 100% 
protection against ECM development in PbA-infected C57BL/6 mice, which eventually 
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died after 3 weeks of infection with hyperparasitemia (Fig. 5a,b). The total abrogation of 
disease development unequivocally reconstituted the effects of CO inhalation on mice 
survival, reported previously in the same ECM model (114). Nevertheless, we observed 
a significant arrest in parasitemia from day 5 p.i to day 7 p.i. only in protective schedules 
of CORM-2 administration (Fig. 4 and Fig 5), which has not been verified in mice 
treated by CO inhalation (114). Moreover, CORM-2 administered at half of the 
concentration (10 mg/kg) or by i.p. route failed to prevent ECM progression (Fig. 4a,b 
and Fig. 5d,e). Importantly, the CORM-2 protective effect was directly demonstrated to 
result from CORM-2-derived CO, since treatment with ALF 466, a molecule similar to 
CORM-2 but without CO groups, revealed ineffective against ECM in all mice tested 
(Fig. 6). Importantly, we also wanted to assess if CORM-2 treatment would induce the 
formation of carboxyhemoglobin, as observed for CO inhalation. Surprisingly, 
immediately after the CORM-2 administration the levels of oxyhemoglobin (O2Hb) and 
carboxyhemoglobin (COHb) revealed no significant differences in the whole blood of 
C57BL/6 infected mice treated with CORM-2 versus DMSO-treated controls or non-
infected mice (Fig. 7a,b). Moreover, by the end of the whole CO or CORM-2 treatment, 
we observed that CO inhalation strongly induced COHb formation, as expected, 
whereas CORM-2 treatment did not (Fig. 7c). Futhermore, at day 6 p.i., DMSO-treated 
controls that developed ECM displayed significantly elevated levels of MetHb, when 
compared with CO-exposed, CORM-2-treated and non-infected mice. (Fig. 7e).  
 
First, these data clearly demonstrates that contrary to CO inhalation, CORM-2 
suppresses ECM without the formation of COHb. This is of extraordinary importance 
regarding potential future therapeutic applications. The observed high levels of MetHb in 
mice that developed ECM, together with an association between CO-prevention of 
pathology and inhibition of MetHb production is in accordance with previous 
observations (114). It has been postulated that the mechanism underlying CO protection 
against ECM consisted of preventing Hb oxidation by virtue of CO binding to Hb, 
generating COHb. This would lead to inhibition of conversion of Hb to MetHb and further 
heme release (114). MetHb and free heme are known to promote oxidative damage and 
inflammation. In fact, heme pathogenic activity in CM has been supported by 
demonstrating that free heme, in the presence of ROS, promotes disruption of BBB tight-
junction function. The protective pheonotype conferred by CO in the murine model is 
reverted by heme administration (114). Given that CORM-2 treatment does not induce 
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COHb formation, we can not argue the same mechanism proposed for CO inhalation to 
explain the protective action of CORM-2. Since CO donated by CORM-2 did not bound 
to Hb we should rule out the possibility of NO-CO interaction to suppress ECM 
pathogenesis, as had been hypothesized (114). This supposition was based on the 
observation that low NO bioavailability associated with ECM onset and appears to result 
in part from Hb scavenging of NO (141). Therefore, it was postulated that COHb 
formation could be limiting NO low bioavailability. However, MetHb levels were found 
significantly reduced in the CORM-2 treated mice, which can indicate that an anti-
oxidant effect is also implicated in the therapeutic action of the compound. 
 
We were also interested to assess whether CORM-2 could mimic the suppressing 
parasite accumulation/sequestration in the brain as seen for CO inhalation. We verified 
that, likewise to CO inhalation treatment, mice treated with CORM-2 were protected from 
ECM development and showed lower amounts of iRBCs in the brain, assessed using an 
real-time imaging system and confirmed by qRT-PCR (Fig. 8, 9a). These observations 
corroborate the preceding results obtained with CO-administration, further evidencing 
the significance of brain iRBC sequestration for ECM onset in the murine model. These 
results suggest that CO-mediated protection from CM seems to be dependent on the 
inhibition of parasite sequestration in the brain.  
 
Furthermore, we assessed blood-brain barrier (BBB) disruption and neuroinflammation, 
to better characterize de protected phenotype ensuing from CORM-2 treatment. We 
confirmed by qRT-PCR that, like CO, CORM-2 conferred ECM resistance was 
associated with the inhibition of CD8+ T cell recruitment to the brain and suppression of 
IFN-γ and ICAM-1 expression in the brain (Fig. 9b-e), two molecules known to play a 
critical role in the cerebral pathology (70, 94), and known to be inhibited in response to 
CO exposure (114). Importantly, BBB barrier was not compromised in the CORM-2 
treated mice (Fig. 10), similarly to what is observed upon CO treatment (114). Altogether 
these results support that CORM-2 protection against ECM pathogenesis result from the 
suppression of the same crucial pathogenic events as CO inhalation, namely parasite 
sequestration, neuroinflammation and BBB disruption. 
 
On the other hand, during CORM-2 treatment we observed a significant delay in the 
progression of parasitemia between days 5 and 7 after infection, which does not occur 
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during CO administration by inhalation. In order to assessed whether this effect resulted 
from impairment in the parasite intra-erythrocytic development we looked at the 
proportion of the circulating blood stage forms at day 6 after infection, when all the mice 
treated with DMSO vehicle where showing signs of ECM. We observed in the blood of 
CORM-2 treated mice a significant reduction in the percentage of ring forms, and an 
increase in the presence of trophozoite and schizont forms as compared to the controls 
receiving DMSO and developing ECM. A decrease in the proportion of gametocytes was 
also verified in the mice receiving CORM-2 (Fig. 11). The biasing through middle-later 
stages of infection upon CORM-2 treatment suggests that CORM-2 might be arresting 
transitorily the parasite development inside the red blood cell, impairing the burst of 
shizonts and release of merozoites and/or affecting merozoite establishment of new 
infections. On the other hand, the presence of more trophozoites/schizonts in circulation 
observed in the CORM-2 protected mice can likely be a consequence of the suppression 
of parasite sequestration, namely in the brain, as we know that Plasmodium parasites 
sequester principally at later stages of development, namely at mature trophozoite and 
schizont stages. A previous work supports this idea, reporting that in synchronous 
infections of P. berghei ANKA, the disappearance of schizonts from circulation was 
associated with the sequestration of these forms in the microvasculature of organs in 
C67BL/6 mice (44). 
 
P. berghei shows a preference for reticulocyte invasion. Thus, we sought to test if 
CORM-2 was affecting erythropoiesis and consequently, the production of reticulocytes. 
If that would be the case, then the arrest in parasitemia could be easily explained by the 
unavailability of enough reticulocytes. In P. berghei this preference has been postulated 
to be ~150-fold higher for reticulocytes than for mature RBCs, which were demonstrated 
to account for the reduced levels of reticulocytes, particularly at later stages of infection 
(186). As expected, in our experiments, infection led to a marked reduction in circulating 
reticulocytes at day 6 after infection. This decrease arises probably as a consequence of 
both hemolysis and insufficient erythropoiesis, observed during malaria infections (136), 
besides due to P. berghei preference for reticulocytes. At day 6 p.i. the reticulocytemia 
showed small but significant differences between CORM-2 and DMSO-treated mice. We 
additionally calculated the reticulocyte index, which is a more appropriate measure of 
reticulocytosis, correcting for hematocrit values. Reticulocyte index did not show 
significant differences between mice receiving CORM-2 or DMSO vehicle, which 
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developed ECM (Fig. 12). These results suggest that CORM-2 treatment does not 
induce significant alterations in reticulocytosis and therefore, the parasitemia arrest 
observed possibly relies on a different explanation.  
 
We further assessed the effect of CORM-2 in the hematological status of the treated 
mice. We observed an important reduction in hematocrit, consistent with a decrease in 
the number of circulating RBCs and the total concentration of Hb, in mice that were 
protected by CORM-2 administration (Fig. 13). The effect on hematocrit can result from 
an increased RBC destruction and/or removal of RBCs from circulation by the spleen, 
which can be conceived to lead to the observed arrest in parasitemia. In agreement with 
this, we observed larger spleens in the CORM-2 treated mice, as compared with the 
controls receiving DMSO, developing ECM, and the non-infected mice (Fig.16). In fact, 
spleen has a crucial role during malaria infection, either by being a major site of 
damaged and infected erythrocyte clearance as well as a critical organ in the 
development of parasite-specific immune responses, through T and B cell 
activation/proliferation (192). Indeed, during P. falciparum infection, splenomegaly 
(abnormal spleen enlargement) is commonly observed and has been associated with an 
increased capacity of RBC filtration (36). Regarding the decrease in hematocrit, a 
hemolytic action of CORM-2 should not be excluded and should be clarified in the future. 
We should additionally say that the observed reduction in hematocrit could explain the 
reduced O2Hb levels observed in the CORM-2 treated mice. 
 
We also observed that there was significant increase in circulating monocytes and 
neutrophils upon CORM-2 treatment comparatively with the DMSO controls, while 
lymphocyte numbers were not significantly altered between these groups (Fig. 15). It is 
known that macrophages and neutrophils sequester in the brain microvasculature during 
cerebral pathology (72, 52). These cells contribute directly to the vascular congestion, 
where they are though to play an important role in attracting T cells to the brain through 
the release of chemokines. In fact, this initial involvement in the development of 
pathogenesis is suggested by the observation that depletion of macrophages or 
neutrophils early in infection prevents ECM onset (81, 82). Thereby, the increased 
presence of monocytes, which will differentiate in macrophages upon activation and 
recruitment to tissues,  and neutrophils in circulation in mice treated with CORM-2 may 
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reflect a decreased recruitment of these cells to the inflamed tissues, namely to the 
brain, contrary to what occurs in the DMSO controls that develop ECM.  
 
We did not characterize the splenic immune responses to infection that would be of 
significant interest. In fact, the spleen enlargement observed in the CORM-2 treated 
mice may reflect that CORM-2 treatment favors the retention of effector T cells in the 
spleen, which could enhance the anti-parasite immunity and explain the observed arrest 
in parasitemia. Supporting this view, a recent work demonstrates that likewise to CORM-
2 treated mice, IP-10 -/- mice are protected against ECM and show an arrest in 
parasitemia from day 5 p.i. to day 11 p.i. (46). Moreover, IP-10 deficiency confers a 
phenotype similar to that of CORM-2-treated mice, reducing leukocyte infiltration and 
iRBC sequestration in the brain microvasculature. Importantly, the parasitemia arrest 
observed in the IP-10 -/- mice was correlated with an increased retention of T cells in the 
spleen and enhancement of their protective immune response against the parasite, 
particularly of CD4+ T cells. This led to the conclusion that suppression of T cell 
migration to the brain, resulting from lack of IP-10, reinforced the protective immune 
response mounted by the spleen over immunopathogenesis, resulting in parasite 
control. A similar process could be occurring with CORM-2 treatment since it also 
inhibits T cell recruitment to the brain and a similar arrest in parasitemia. Furthermore, 
we have shown that CO down-regulates IP-10 expression in the brain, and the same 
effect is presumable occurring with CORM-2 treatment. However, these hypotheses 
remain elusive and future work must be carried out to test them. 
 
Whether the arrest in parasitemia could be contributing to the protection against ECM is 
not know. Nevertheless, a recent study indicates that this might not be the case. Baptista 
et al. (47, submitted) showed that treatment with an anti-malarial prior to the day of ECM 
onset strongly reduced the parasite in circulation, however did not protected mice from 
developing ECM later on, around day 14 p.i., when parasitemia was increased again. 
Although the experimental conditions are obviously not the same, this might elucidate 
that parasitemia control may be a consequence, as suggested before, than a cause of 
protection against ECM, during CORM-2 treatment. 
 
Moreover, we also verified that the number of platelets in circulation showed no 
significant differences between CORM-2-treated mice and DMSO controls. Platelets 
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from CORM-2 treated group have significant smaller average volumes when compared 
with DMSO-treated mice, indicating that in CORM-2 protected mice there is a decrease 
in platelet aggregation (Fig 14). This effect is consistent with previous work showing that 
both CO and CORM-2 inhibit platelet aggregation (125, 157). Indeed, it is plausible that 
this effect is contributing to the protection against ECM, since platelets have been 
associated with both murine and human CM (95, 97). Among other processes, platelet 
aggregates associated with iRBCs (platelet-mediated clumping) may contribute to 
microvascular congestion during CM (33). Due to the potential pathogenic role of 
platelets, thrombocytopenia, which is commonly observed during human and 
experimental CM, has been suggested to make part of the host protective response 
against pathogenesis (99). Accordingly, we observed that thrombocytopenia is marked 
in all infected mice (Fig. 14a). These results suggests that CORM-2 protective effect 
against ECM relies not only in preventing neuroinflammation and parasite sequestration, 
but also in inhibiting hemostasis dysfunction, three processes invoked to contribute to 
CM (21).  
 
Finally, we were also interested to investigate the effect of CORM-2 in RBC 
deformability. We observed that CORM-2 treatment inhibits the loss of deformability of 
RBCs during infection, comparatively to DMSO controls, at the day of ECM development 
in this later group (Fig. 17). The increased RBC deformability in CORM-2 treated mice 
might be playing a role in the CORM-2-associated protection against ECM. It is thereby 
important to repeat the assessment of RBC deformability to confirm the effect of CORM-
2 in preventing loss of RBC deformability during infection. 
 
Reduced RBC deformability is a strong predictor of human malaria severity (188, 189). It 
is proposed that an increased rigidity of both uninfected and RBCs significantly accounts 
for microvasculature congestion and contributes to impairment of microcirculatory blood 
flow (35). The loss of deformability has been suggested to result from oxidative damage 
of RBC membranes triggered by hemoglobin-derived products released into circulation 
during schizont rupture. In fact, it was shown that hemin directly induces RBC rigidity in 
a dose-dependent manner and supports the use of anti-oxidants as effective adjunctive 
therapy to prevent malaria mortality (190). Moreover, conversion of Hb to MetHb inside 
the RBC, elicited by ROS and NO produced during inflammation, leads to increased 
RBC rigidity (193). Indeed, CORM-2 treatment decreases MetHb levels in peripheral 
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blood. Thereby CORM-2 enhancement of RBC deformability may reflect its capacity to 
ameliorate the pro-oxidant state that occurs during infection, and possibly contribute to 
the improvement of disease outcome. 
 
7. Concluding Remarks and Future Work 
In summary, the results obtained in the present work further revealed the mechanisms 
underlying CO protection against ECM and demonstrate that the administration of CO-
releasing molecules, namely CORM-2, can mimic CO protection against the cerebral 
pathology in PbA-infected C57BL/6 mice. Our data strongly supports that CO protective 
effect against ECM is not only achieved by suppressing neuroinflammation and BBB 
disruption but also by inhibiting parasite sequestration in the brain. Moreover, inhibition 
of IP-10 mediated chemotaxis also seems to be implicated in CO protective effect in 
ECM.  
 
CORM-2 administration reproduces the CO-induced protection observed in ECM, by 
reducing neuroinflammation, BBB disruption, parasite sequestration in the brain and 
MetHb formation, but does not induce the formation of COHb. Treatment with the CO 
donor is associated with an arrest in parasitemia. Its origin and importance for protection 
against ECM is not clear. Hemolysis due to CORM-2 molecule might be occurring in 
association with enhanced removal of RBCs by the spleen. It could also be that 
increased retention of T cells in the spleen improve anti-parasite immune responses and 
control parasite load. CORM-2 also limits platelet aggregation and increases RBC 
deformability and these effects are likely related with its protective action.  
 
Altogether, the results indicate that CO protective mechanisms observed during P. 
berghei infection involve the reestablishment of hemostasis equilibrium and prevention 
of oxidative stress. Moreover, the results obtained with CORM-2 sustain that a potential 
CO-based therapy could be applied, circumventing the clinical toxicity of CO inhalation. 
Indeed, we have preliminary results showing that an improved version of CORM-2, with 
the advantage of being water soluble, prevents ECM development as well, but does not 
seem to affect parasite load. This molecule could constitute another interesting 
candidate for future pharmaceutical purposes. 
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In future work, we would like to understand the relevance of splenic immune responses 
and chemotaxis processes as well as the regulation of hemostasis in CORM-2 treatment 
during ECM. Futhermore, we would like to test different CO-RMs drug candidates, 
organometallic and organic compounds, in ECM as well as in other models of severe 
malaria such as the rodent model of malaria-associated respiratory distress syndrome  
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8. Materials and Methods 
 
8.1. Mice 
C57BL/6 and BALB/c wild-type mice were bred in the pathogen-free facilities of the 
Instituto Gulbenkian de Ciência and housed in the pathogen-free facilities of the Instituto 
de Medicina Molecular. All protocols were approved by and conducted according to the 
Animal Care regulations of the Direcção Geral de Veterinária. 
 
8.2. Parasites, infection and disease assessment 
We used red blood cells infected with green fluorescent protein (GFP)-transgenic P. 
berghei ANKA (185), luciferase-transgenic P. berghei ANKA clone 676m1cl1 (194), 
which expresses luciferase constitutively during the whole life cycle, or P. berghei ANKA 
clone 354cl4, which expresses luciferase in schizonts (44) to infect mice. C57BL/6 or 
BALB/c mice with 6- to 8-week-old were infected by intraperitoneal (i.p.) injection of 106 
infected red blood cells (iRBCs), except in experiments using CO-treated mice infected 
with P. berghei ANKA clone 676m1cl1, where 105 iRBCs were inoculated or CORM-2 
treated mice infected with P. berghei ANKA clone 354cl4, were 5x105 iRBCs were 
inoculated. Infected mice were monitored daily for clinical symptoms of experimental 
cerebral malaria (ECM) including hemi- or paraplegia, head deviation, tendency to roll 
over on stimulation, ataxia and convulsions. Mice showing severe signs of ECM at day 
5, 6 or 7 post-infection (p.i.) were sacrificed. Parasitemia was assessed by flow 
cytometry for mice infected with GFP-expressing P. berghei ANKA, using tail blood, as 
previously described (GFP ref.). For mice infected with luciferase-expressing P. berghei 
ANKA clone 676m1cl1 or P. berghei ANKA clone 354cl4 parasitemia was determined by 
Giemsa-stained blood smears, using tail blood, followed by microscopic counting. Mean 
parasitemia is expressed as percentage of infected red blood cells. Survival is 
expressed as percentage. 
 
8.3. CO exposure  
Mice were placed in a gastight 60-liter capacity chamber and exposed to CO at 250 
p.p.m. for 24h between day 2 and 3 p.i., as described before (114). In brief, 1% CO (Aga 
Linde) was mixed with air in a stainless steel cylinder to obtain a final concentration of 
250 p.p.m. CO was provided continuously at a flow rate of ~ 12 liter/min. We monitored 
CO concentration using a CO analyzer (Interscan Corporation).  
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8.4. Visualization and quantification of bioluminescence in organs ex vivo 
Bioluminescence assessment of mice organs was performed for P. berghei ANKA-
infected C57BL/6 mice when ECM symptoms developed (day 5-6 p.i.). and in P. berghei 
ANKA-infected C57BL/6 mice treated with CO or CORM-2 later on (d6-12 p.i.) in order to 
confirm that mice would not develop ECM. Bioluminescence was visualized and 
quantified in using an intensified-charge-coupled device (I-CCD) photon-counting video 
camera from the in vivo Imaging System IVIS Lumina (Xenogen), as described 
previously (44). The animals were injected i.p. with D-luciferin Firefly Potassium Salt 
(Caliper Life Sciences) dissolved in D-PBS 1x (Dulbecco's Phosphate-Buffered Saline, 
without Ca2+ and Mg2+; Invitrogen) (150 mg/kg of body weight) and 10 min. after mice 
were sacrificed by CO2 inhalation and perfused intracardially with 10 ml of PBS 1x 
(Phosphate-Buffered Saline; Sigma-Aldrich) to remove cells in circulation. Organs were 
dissected, washed in PBS 1x and imaged immediately, with a 15-cm field of view, a 
small binning factor, and exposure times of 15 or 20 sec, for all organs, and 300 sec for 
the brains. Bioluminescence in the individual organs was quantified by using the 
software Living Image (Xenogen), applying a region-of-interest adjusted to the organs 
shape. The results are shown as mean average radiance (photons per second per cm2 
per steradian; p/s/cm2/sr; x 104 or x 106). 
 
8.5. Quantitative Real-Time PCR 
Mice developing were sacrificed by CO2 inhalation and intracardially perfused with 10ml 
of PBS 1x. Brains were removed, minced and total RNA was extracted by using TRIzol 
(Invitrogen) and subsequently an RNAeasy Mini Kit (Quiagen) accordingly to the 
manufacturer protocols. RNA was converted to cDNA by a Transcriptor First Strand 
cDNA Synthesis Kit (Roche) according to the manufacturer instructions in a MyCycler 
thermocycler (BioRad). For quantitative PCR, cDNA was amplified in a total reaction 
volume of 25 µl with half of the volume (12.5 µl) of Power SYBR Green PCR Master Mix 
(Applied Biosystems) in a ABI Prism 7000 Sequence Detection System and by ABI 
Prism SDS 7000 software (Applied Biosystems). Each sample was assayed in duplicate. 
Thermal cycler program consisted in one cycle of 2 min at 50°C, followed by one cycle of 
10 min at 95°C, 45 cycles of 15 sec at 95°C and 1 min at 60°C. Parasite brain 
accumulation/sequestration and neuroinflammation was assessed by the quantification 
of mRNA expression of P. berghei 18S ribosomal RNA (r18S) gene and several 
inflammatory genes related with ECM, respectively. The primer (Thermo Scientific) 
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sequences used are as follows: HPRT: Fwd: 5’–GTA ATG ATC GTC AAC GGG GGA 
C–3’; Rev: 5’–CCA GCA AGC TTG CAA CCT TAA CCA–3’; P.berghei r18S: Fwd: 5’–
AAG CAT TAA ATA AAG CGA ATA C … TAC–3’; Rev: 5’–GGA GAT TGG TTT TGA 
CGT TTA TGT G–3’; CD3: Fwd: 5’–TCT CGG AAG TCG AGG ACA GT–3’; Rev: 5’-ATC 
AGC AAG CCC AGA GTG AT–3’; CD8 β: Fwd: 5’- GCT GGT AGT CTG CAT CCT GCT 
TC–3’; Rev: 5’–TTG GTA GCA GGC TAT CAG TGT TGT G-3’; Granzyme B: Fwd: 5’-
CTA AAG CTG AAG AGT AAG GCC AAG-3’; Rev: 5’-GAT CCT TCT GTA CTG TCA 
GCT CAA-3’. CXCR3: Fwd: 5’ AAT GCC ACC CAT TGC CAG TAC-3’; Rev: 5’-AGC 
AGT AGG CCA TGA CCA GAA G-3’; IP-10: Fwd: 5’-GAC GGT CCG CTG CAA CTG-3’; 
Rev: 5’-GCT TCC CTA TGG CCC TCA TT-3’. RNA levels were normalized to the 
expression of the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase 
(hprt). Standard curves were obtained by serial dilutions of brain cDNA. Relative 
quantification of mRNA expression was determined using the Pfaffl method (195). The 
results are shown as percentage of mRNA mean expression in C57BL/6 P. berghei-
ANKA infected mice, which developed ECM. 
  
8.6. CO-releasing molecules administration 
Tricarbonyldichlororuthenium (II) dimer (CORM-2) (Sigma-Aldrich) and ALF466 
(ALFAMA) were solubilized in 10% dimethyl sulfoxide (DMSO; Sigma-Aldrich) in PBS 
1x. CORM-2 solution (10mg/kg or 20mg/kg of body weight) was administered 
intravenously (i.v.) according to the chosen schedules. ALF 466 was administered i.v. at 
equimolar concentrations relatively to CORM-2. A solution of 10% DMSO in PBS 1x 
administered i.v. was used as a vehicle control solution. The concentrations of CORM-2 
used in the present study were based on previous reports (159, 171). 
 
8.7. Quantification of O2Hb, and MetHb and COHb 
Blood was collected from mice tail in capillary tubes (VWR) with heparin (100 i.u../ml in 
PBS 1x; LEO Pharma Inc.) and transferred into AVOXimeter 4000 cuvettes (ITC) where 
the levels of carboxyhemoglobin (COHb), oxyhemoglobin (O2Hb) and methemoglobin 
(MetHb) were measured in a portable AVOXimeter 4000 CO-oximeter (ITC). Results are 
shown as mean percentage of total hemoglobin species in circulation. 
 
 
 
 68 
8.8. BBB permeability  
Blood-Brain Barrier (BBB) permeability was assessed using the Evan’s blue technique, 
fundamentally as described before (196) Briefly, mice were i.v. with 0.2 ml of PBS 1–2% 
Evans blue (EB) (Sigma) when clinical symptoms of ECM were observed in mice treated 
with DMSO vehicle solution. Mice were killed 1 h thereafter, and brains were weighed 
and placed in 2 ml formamide (Merck) for 24 h at 37 ºC to extract EB dye from the 
tissue. Absorbance was measured at λ = 620 nm (EB absorbance) in a DU 70 
Spectrophotometer (Beckman). Evans blue concentration was calculated using a 
standard curve of EB dye. The data are expressed as mg of Evans blue per g of brain 
tissue. 
 
8.9. Flow cytometry analysis 
Blood from mice infected with P.berghei ANKA GFP-expressing parasites was collected 
from the tail into tubes with heparin (100 i.u./ml in PBS 1x). 
To differentiate parasite blood stages, 10 µl of blood suspension was stained with the 
dsDNA vital dye Hoechst-33342 (Invitrogen) diluted in PBS 1x, for 30 min, at room 
temperature, in the dark, followed by FACS analysis. Red blood cells (RBCs) were 
selected on the basis of size (forward-scatter, FSC) and granulosity (side-scatter, SSC). 
Parasite ring forms (R) were gated on the Hoechstlow GFPlow RBC population. 
Trophozoites and schizonts (T/S) were gated on the Hoechsthigh GFPint RBCs and 
gametocytes (G) on the Hoechstint GFPhigh RBC population, based on previous work 
(183). low, int, high correspond to low, intermediate or high fluorescence intensity, 
respectively. Infected RBCs (iRBCs) were gated on the Hoechst+ GFP+ RBC population. 
Proportion of parasite blood stages are shown as mean percentage of total iRBCs. 
To determine reticulocytemia and reticulocyte number, blood cells were stained for 
CD71 and CD45. CD71 corresponds to the transferrin receptor, which is expressed in 
reticulocytes but also in activated leukocytes. For this reason a staining for CD45, a 
tyrosine phosphatase expressed in all leukocytes, was also included to discriminate 
these cells. First, 2 µl of blood suspension were washed (200 µl of PBS 1x 
supplemented with 2% fetal bovine serum (FBS; Invitrogen)) in a 96-well plate, 
centrifuged (7 min, 4ºC, 453 g) and supernatant discarded. Cells were incubated in 50 µl 
of FcBlock anti-mouse CD16/CD32 (clone 93; eBioscience) for 20 min, on ice, to block 
unspecific binding of antibodies to cells. Cells were further washed (150 µl PBS 1x with 
2% FBS), centrifuged (7 min, 4ºC, 453 g) and supernatant was discarded. Then, cells 
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were incubated with 50 µl of a mix of phycoerythrin (PE)-conjugated anti-mouse CD71 
(clone RI7 217.1.4, Caltag) and allophycocyanin(APC)-conjugated anti-mouse CD45.1 
(clone A20; eBioscience) antibodies, diluted in PBS 1x with 2% FBS, for 20 min, on ice, 
in the dark. After that, cells were washed (150 µl PBS 1x with 2% FBS), centrifuged (7 
min, 4ºC, 453 g), ressuspended (200 µl PBS 1x with 2% FBS) and analysed in the 
FACS. Cell number was determined using latex beads (10 µm; Beckman Coulter). 
Briefly, 2 µl of blood was diluted in 480 µl PBS 1x supplemented with 2% FBS, followed 
by addition of 20 µl of latex beads and analyses of the mixture in the FACS. As the 
concentration of beads is known and RBCs are acquired at the same time, it is possible 
to determine the number of RBCs equivalent to a certain number of beads, which, in 
turn, will indicate the correspondent volume acquired. This allows the determination of 
RBCs per volume (ml). RBCs were selected on the basis of size and granulosity (FSC 
and SSC) and additionally gated on the CD45- population. Then, reticulocytes were 
gated in the CD71+ RBC population. Results are shown as mean percentage of 
reticulocytes in the total RBC population and mean absolute number of parasitized 
reticulocytes (CD71+GFP+ RBCs) per ml of blood (x107).Reticulocyte index (%) was 
calculated using the formula: reticulocytes (%) x (hematocrit/hematocrit of uninfected 
mice). Hoechst stain and indicated antibodies were used at saturating concentrations. 
FACS analysis was performed on a FACS-Calibur instrument run with the CellQuest 
program (Becton and Dickinson). Data analysis was performed with FlowJo software 
(Tree Star).  
 
8.10. Hematocrit and Hemogram 
Mice were sacrificed by CO2 inhalation, an blood was collected from the heart with a U-
100 insulin 1 ml syringe (Terumo) with 20 µl heparin (100 i.u./ml in PBS 1x) and 
transferred to a 1 ml tube with EDTA (Normax). Samples were analysed by DNAtech. 
Hematocrit is shown as mean percentage of RBC volume in the total blood volume; RBC 
number is indicated as the mean number of RBCs per ml of blood (x 109) and 
hemoglobin concentration is shown as mean g of hemoglobin per dl of blood. Platelet 
quantity is expressed as number of platelets per ml of blood (x 106) and average volume 
of platelets is shown as mean µm. Results for absolute cell count of monocytes, 
neutrophils and lymphocytes are shown as mean number per ml of blood (x 106) 
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8.11. RBC deformability 
Mice were sacrificed by CO2 inhalation and blood was collected from the heart to tubes 
with EDTA. Red blood cell deformability was measured as described previously (197). 
Briefly, deformability at different shear stress (0.30, 0.60, 1.20, 3.0, 12.0, 30.0, 60.0 
Pascal) was determined by using the Rheodyn SSD shear stress difractometer from 
Myrenne GMBH (Roentgen). RBC deformability is expressed as the elongation index 
(EI) in percentage. Rheodyn SSD difractometer determines RBC deformability by 
simulating shear forces exerted by blood flow and vascular walls on erythrocytes. 
 
8.12. Statistical analysis  
Kolmogorov-Smirnov test was applied to confirm normal distribution of data. An unpaired 
Student’s T test was then applied to evaluate statistical significant differences between 
mean values. P < 0.05 was considered significant. 
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